UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
☒ QUARTERLY REPORT PURSUANT TO SECTION
13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30,
2023
OR
☐ TRANSITION REPORT PURSUANT TO
SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from __________ to
__________
Commission File Number: 001-41138
GENESIS GROWTH TECH ACQUISITION CORP.
(Exact name of registrant as specified in its
charter)
Cayman Islands | | 001-41138 | | 98-1601264 |
(State or other jurisdiction of incorporation or organization) | | (Commission File Number) | | (I.R.S. Employer Identification No.) |
Bahnhofstrasse 3 Hergiswil Nidwalden, Switzerland | | 6052 |
(Address of Principal Executive Offices) | | (Zip Code) |
+41 78 607 99 01
(Registrant’s telephone number, including
area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | | Trading Symbol(s) | | Name of each exchange on which registered |
Units, each consisting of one Class A ordinary share, $0.0001 par value, and one-half of one redeemable warrant | | GGAAU | | The Nasdaq Stock Market LLC |
Class A ordinary shares par value $0.0001 per share, included as part of the units | | GGAA | | The Nasdaq Stock Market LLC |
Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share | | GGAAW | | The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant
(1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12
months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements
for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant
has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405
of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.
See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,”
and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer | ☐ | | Accelerated filer | ☐ |
Non-accelerated filer | ☒ | | Smaller reporting company | ☒ |
| | | Emerging growth company | ☒ |
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant
is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☒ No ☐
As of November 9, 2023, 101,039 Class A ordinary
shares, par value $0.0001 per share, and 6,325,000 Class B ordinary shares, par value $0.0001 per share, were issued and outstanding.
GENESIS GROWTH TECH ACQUISITION CORP.
Form 10-Q
Table of Contents
PART
I. FINANCIAL INFORMATION
Item 1. Financial
Statements
GENESIS GROWTH TECH ACQUISITION CORP.
BALANCE SHEETS
UNAUDITED
| |
September 30, 2023 | | |
December 31, 2022 | |
Assets: | |
| | |
| |
Current assets: | |
| | |
| |
Cash | |
$ | — | | |
$ | — | |
Due from related party | |
| — | | |
| 1,200,595 | |
Prepaid expenses | |
| 49,970 | | |
| 208,721 | |
Total current assets | |
| 49,970 | | |
| 1,409,316 | |
| |
| | | |
| | |
Investments held in Trust Account | |
| 1,034,847 | | |
| 262,960,151 | |
Total Assets | |
$ | 1,084,817 | | |
$ | 264,369,467 | |
| |
| | | |
| | |
Liabilities, Class A Ordinary Shares Subject to Possible Redemption and Shareholders’ Deficit: | |
| | | |
| | |
Current liabilities: | |
| | | |
| | |
Cash Overdraft | |
$ | 871 | | |
$ | — | |
Accounts payable & accrued expenses | |
| 2,609,166 | | |
| 2,979,230 | |
Note payable - related party | |
| 2,307,717 | | |
| 2,530,000 | |
Deferred underwriting commissions | |
| — | | |
| 13,915,000 | |
Total Liabilities | |
| 4,917,754 | | |
| 19,424,230 | |
| |
| | | |
| | |
Commitments and Contingencies | |
| | | |
| | |
Class A ordinary shares subject to possible redemption; 81,520 and 25,300,000 shares at redemption value of approximately $14.14 and $10.39 per share at September 30, 2023 and December 31, 2022, respectively | |
| 1,152,658 | | |
| 262,860,151 | |
| |
| | | |
| | |
Shareholders’ Deficit: | |
| | | |
| | |
Preference shares, $0.0001 par value; 5,000,000 shares authorized; none issued or outstanding | |
| — | | |
| — | |
Class A ordinary shares, $0.0001 par value; 500,000,000 shares authorized; no non-redeemable shares issued or outstanding | |
| — | | |
| — | |
Class B ordinary shares, $0.0001 par value; 50,000,000 shares authorized; 6,325,000 shares issued and outstanding | |
| 633 | | |
| 633 | |
Additional paid-in capital | |
| — | | |
| — | |
Accumulated deficit | |
| (4,986,226 | ) | |
| (17,915,547 | ) |
Total shareholders’ deficit | |
| (4,985,595 | ) | |
| (17,914,914 | ) |
Total Liabilities, Class A Ordinary Shares Subject to Possible Redemption and Shareholders’ Deficit | |
$ | 1,084,817 | | |
$ | 264,369,467 | |
The accompanying notes are an integral part
of these unaudited financial statements.
GENESIS GROWTH TECH ACQUISITION CORP.
UNAUDITED STATEMENTS
OF OPERATIONS
| |
For the Three Months Ended | | |
For the Nine Months Ended | |
| |
September 30, | | |
September 30, | |
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
General and administrative expenses | |
$ | 294,748 | | |
$ | 1,101,589 | | |
$ | 677,870 | | |
$ | 1,685,963 | |
General and administrative expenses - related party | |
| 30,000 | | |
| 30,000 | | |
| 90,000 | | |
| 90,000 | |
Loss from operations | |
| (324,748 | ) | |
| (1,131,589 | ) | |
| (767,870 | ) | |
| (1,775,963 | ) |
| |
| | | |
| | | |
| | | |
| | |
Other income: | |
| | | |
| | | |
| | | |
| | |
Paid-in-kind interest income on investments held in Trust Account | |
| 15,402 | | |
| 1,136,330 | | |
| 1,646,715 | | |
| 1,489,289 | |
Total other income | |
| 15,402 | | |
| 1,136,330 | | |
| 1,646,715 | | |
| 1,489,289 | |
| |
| | | |
| | | |
| | | |
| | |
Net (loss) income | |
$ | (309,346 | ) | |
$ | 4,741 | | |
$ | 878,845 | | |
$ | (286,674 | ) |
| |
| | | |
| | | |
| | | |
| | |
Weighted average Class A ordinary shares - basic and diluted | |
| 94,250 | | |
| 25,300,000 | | |
| 4,990,857 | | |
| 25,300,000 | |
Basic and diluted net (loss) income per share, Class A ordinary shares | |
$ | (0.05 | ) | |
$ | 0.00 | | |
$ | 0.08 | | |
$ | (0.01 | ) |
Weighted average Class B ordinary shares - basic and diluted | |
| 6,325,000 | | |
| 6,325,000 | | |
| 6,325,000 | | |
| 6,325,000 | |
Basic and diluted net (loss) income per share, Class B ordinary shares | |
$ | (0.05 | ) | |
$ | 0.00 | | |
$ | 0.08 | | |
$ | (0.01 | ) |
The accompanying notes are an integral part
of these unaudited financial statements.
GENESIS GROWTH TECH ACQUISITION CORP.
UNAUDITED STATEMENTS
OF CHANGES IN SHAREHOLDERS’ DEFICIT
FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER
30, 2023
| |
Ordinary
Shares | | |
Additional | | |
| | |
Total | |
| |
Class
A | | |
Class
B | | |
Paid-in | | |
Accumulated | | |
Shareholders’ | |
| |
Shares | | |
Amount | | |
Shares | | |
Amount | | |
Capital | | |
Deficit | | |
Deficit | |
Balance - December
31, 2022 | |
| — | | |
$ | — | | |
| 6,325,000 | | |
$ | 633 | | |
$ | — | | |
$ | (17,915,547 | ) | |
$ | (17,914,914 | ) |
Waiver of deferred underwriting
fee | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | | |
| 13,915,000 | | |
| 13,915,000 | |
Increase in redemption value
of Class A ordinary shares subject to possible redemption | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | | |
| (1,616,602 | ) | |
| (1,616,602 | ) |
Net income | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | | |
| 1,352,593 | | |
| 1,352,593 | |
Balance – March 31,
2023 | |
| — | | |
| — | | |
| 6,325,000 | | |
| 633 | | |
| — | | |
| (4,264,556 | ) | |
| (4,263,923 | ) |
Increase in redemption value
of Class A ordinary shares subject to possible redemption | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | | |
| (140,505 | ) | |
| (140,505 | ) |
Net loss | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | | |
| (164,402 | ) | |
| (164,402 | ) |
Balance - June 30, 2023 | |
| — | | |
| — | | |
| 6,325,000 | | |
| 633 | | |
| — | | |
| (4,569,463 | ) | |
| (4,568,830 | ) |
Increase in redemption value
of Class A ordinary shares subject to possible redemption | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | | |
| (107,419 | ) | |
| (107,419 | ) |
Net loss | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | | |
| (309,346 | ) | |
| (309,346 | ) |
Balance - September 30,
2023 | |
| — | | |
$ | — | | |
| 6,325,000 | | |
$ | 633 | | |
$ | — | | |
$ | (4,986,228 | ) | |
$ | (4,985,595 | ) |
FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER
30, 2022
| |
Ordinary
Shares | | |
Additional | | |
| | |
Total | |
| |
Class
A | | |
Class
B | | |
Paid-in | | |
Accumulated | | |
Shareholders’ | |
| |
Shares | | |
Amount | | |
Shares | | |
Amount | | |
Capital | | |
Deficit | | |
Deficit | |
Balance
- December 31, 2021 | |
| — | | |
$ | — | | |
| 6,325,000 | | |
$ | 633 | | |
$ | — | | |
$ | (12,188,269 | ) | |
$ | (12,187,636 | ) |
Net loss | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | | |
| (206,237 | ) | |
| (206,237 | ) |
Balance
- March 31, 2022 (unaudited) | |
| — | | |
| — | | |
| 6,325,000 | | |
| 633 | | |
| — | | |
| (12,394,506 | ) | |
| (12,393,873 | ) |
Increase
in redemption value of Class A ordinary shares subject to possible redemption | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | | |
| (253,637 | ) | |
| (253,637 | ) |
Net loss | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | | |
| (85,178 | ) | |
| (85,178 | ) |
Balance
- June 30, 2022 (unaudited) | |
| — | | |
| — | | |
| 6,325,000 | | |
| 633 | | |
| — | | |
| (12,733,321 | ) | |
| (12,732,688 | ) |
Increase
in redemption value of Class A ordinary shares subject to possible redemption | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | | |
| (1,136,330 | ) | |
| (1,136,330 | ) |
Net income | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | | |
| 4,741 | | |
| 4,741 | |
Balance
- September 30, 2022 (unaudited) | |
| — | | |
$ | — | | |
| 6,325,000 | | |
$ | 633 | | |
$ | — | | |
$ | (13,864,910 | ) | |
$ | (13,864,277 | ) |
The accompanying notes are an integral part
of these unaudited financial statements.
GENESIS GROWTH TECH ACQUISITION CORP.
UNAUDITED STATEMENTS
OF CASH FLOWS
|
|
For the Nine Months Ended
September 30, |
|
|
|
2023 |
|
|
2022 |
|
Cash Flows from Operating Activities: |
|
|
|
|
|
|
Net income (loss) |
|
$ |
878,845 |
|
|
$ |
(286,674 |
) |
Adjustments to reconcile net income (loss) to net cash used in operating activities: |
|
|
|
|
|
|
|
|
Paid-in-kind interest income on investments held in Trust Account |
|
|
(1,646,715 |
) |
|
|
(1,489,289 |
) |
Changes in operating assets: |
|
|
|
|
|
|
|
|
Cash overdraft |
|
|
871 |
|
|
|
— |
|
Prepaid expenses |
|
|
158,751 |
|
|
|
(139,428 |
) |
Accounts payable & accrued expenses |
|
|
(370,064 |
) |
|
|
1,059,673 |
|
Net cash used in operating activities |
|
|
(978,312 |
) |
|
|
(855,718 |
) |
|
|
|
|
|
|
|
|
|
Cash Flows from Investing Activities: |
|
|
|
|
|
|
|
|
Due from related party |
|
|
1,200,595 |
|
|
|
986,995 |
|
Cash withdrawn from Trust Account in connection with redemption |
|
|
263,572,019 |
|
|
|
— |
|
Net cash provided by investing activities |
|
|
264,772,614 |
|
|
|
986,995 |
|
|
|
|
|
|
|
|
|
|
Cash Flows from Financing Activities: |
|
|
|
|
|
|
|
|
Repayment of note payable to related party |
|
|
(530,000 |
) |
|
|
(228,077 |
) |
Proceeds from note payable to related party |
|
|
307,717 |
|
|
|
— |
|
Offering costs |
|
|
— |
|
|
|
96,800 |
|
Redemption of ordinary shares |
|
|
(263,572,019 |
) |
|
|
— |
|
Net cash used in financing activities |
|
|
(263,794,302 |
) |
|
|
(131,277 |
) |
|
|
|
|
|
|
|
|
|
Net change in cash |
|
|
— |
|
|
|
— |
|
Cash - beginning of the period |
|
|
— |
|
|
|
— |
|
Cash - end of the period |
|
$ |
— |
|
|
$ |
— |
|
|
|
|
|
|
|
|
|
|
Supplemental disclosure of noncash financing activities: |
|
|
|
|
|
|
|
|
Waiver of deferred underwriting fee |
|
$ |
13,915,000 |
|
|
$ |
— |
|
Accretion of common share subject to redemption |
|
$ |
1,864,526 |
|
|
$ |
1,389,967 |
|
The accompanying notes are an integral part
of these unaudited financial statements.
GENESIS GROWTH TECH ACQUISITION CORP.
NOTES TO UNAUDITED
FINANCIAL STATEMENTS
NOTE 1 - DESCRIPTION OF ORGANIZATION, BUSINESS
OPERATIONS AND GOING CONCERN
Genesis Growth Tech Acquisition Corp. (the “Company”)
was incorporated as a Cayman Islands exempted company on March 17, 2021. The Company was incorporated for the purpose of effecting a
merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses
or entities (the “Business Combination”). The Company is an emerging growth company and, as such, the Company is subject
to all of the risks associated with emerging growth companies.
As of September 30, 2023, the Company had not
commenced any operations. All activity for the period from March 17, 2021 (inception) through September 30, 2023, relates to the Company’s
formation and the initial public offering (the “Initial Public Offering”) described below, and, subsequent to the Initial
Public Offering, identifying a target company for a Business Combination. The Company will not generate any operating revenues until
after the completion of its initial Business Combination, at the earliest. The Company generates non-operating income from the proceeds
derived from the Initial Public Offering and placed in a Trust Account (as defined below).
The Company’s sponsor is Genesis Growth
Tech LLC, a Cayman Islands limited liability company (the “Sponsor”). The registration statement for the Company’s
Initial Public Offering was declared effective on December 8, 2021. On December 13, 2021, the Company consummated its Initial Public
Offering of 22,000,000 units (the “Units” and, with respect to the Class A ordinary shares included in the Units being offered,
the “Public Shares”), at $10.00 per Unit, generating gross proceeds of $220.0 million and incurring offering costs of approximately
$19.0 million, of which $12.1 million was for deferred underwriting fees for costs relating to the Initial Public Offering. The Company
granted the underwriters a 45-day option to purchase up to an additional 3,300,000 Units at the Initial Public Offering price to cover
over-allotments. On December 21, 2021, the underwriters pursuant to the full exercise of the over-allotment option, purchased 3,300,000
Units. The over-allotment units were sold at the offering price of $10.00 per Unit, generating additional gross proceeds to the Company
of $33.0 million. The Company incurred additional offering costs of approximately $2.1 million in connection with the over-allotment,
of which approximately $1.8 million was for deferred underwriting commissions (see Note 5). On January 26, 2023, Nomura Securities International,
Inc. (“Nomura”) the underwriter for the initial public offering of the Company, pursuant to a letter dated as of the same
date, waived its entitlement to the payment of the deferred underwriting discount then payable to Nomura in connection with the Initial
Public Offering and pursuant to the prior underwriting agreement between Nomura and the Company dated December 8, 2021. Other than such
waiver, the letter did not waive any rights or obligations of the Company or Nomura which survive the termination of the underwriting
agreement.
Simultaneously with the closing of the Initial
Public Offering, the Company consummated the private placement (“Private Placement”) of 8,050,000 warrants (each, a “Private
Placement Warrant” and collectively, the “Private Placement Warrants”), at a price of $1.00 per Private Placement Warrant
to the Sponsor, generating proceeds of approximately $8.1 million. In connection with the full exercise of the over-allotment option
on December 21, 2021, the Sponsor purchased an additional 825,000 Private Placement Warrants at a purchase price of $1.00 per Private
Placement Warrant, generating additional gross proceeds to the Company of $825,000 (Note 4).
Upon the closing of the Initial Public Offering,
the over-allotment and the Private Placement, $253 million (or $10.00 per Unit) of the net proceeds of the sale of the Units in the Initial
Public Offering, the over-allotment and the Private Placement Warrants in the Private Placement were placed in a trust account (“Trust
Account”), located in the United States, with Continental Stock Transfer & Trust Company acting as trustee, and will invest
only in United States “government securities” within the meaning of Section 2(a)(16) of the Investment Company Act 1940,
as amended (the “Investment Company Act”), having a maturity of 185 days or less or in money market funds meeting certain
conditions under Rule 2a-7 promulgated under the Investment Company Act that invest only in direct U.S. government treasury obligations.
Except with respect to interest and other income earned on the funds held in the Trust Account that may be released to the Company to
pay taxes, if any, and up to $100,000 for dissolution costs, the proceeds from the Initial Public Offering, the over-allotment and the
sale of the Private Placement Warrants will not be released from the Trust Account until the earliest of (i) the completion of an initial
Business Combination, (ii) the redemption of the Company’s public shares if the Company does not complete an initial Business Combination
within the Combination Period (as defined below), subject to applicable law, or (iii) the redemption of the Company’s Public Shares
properly submitted in connection with a shareholder vote to approve an amendment to the Company’s amended and restated memorandum
and articles of association.
GENESIS GROWTH TECH ACQUISITION CORP.
NOTES TO UNAUDITED FINANCIAL STATEMENTS
The Company’s management has broad discretion
with respect to the specific application of the net proceeds of the Initial Public Offering, the over-allotment and the sale of Private
Placement Warrants. Although substantially all of the net proceeds are intended to be applied generally towards consummating a Business
Combination, there is no assurance that the Company will be able to complete a Business Combination successfully. The Company must complete
one or more initial Business Combinations having an aggregate fair market value of at least 80% of the assets held in the Trust Account
(excluding the deferred underwriting commissions and taxes payable on the interest and other income earned on the Trust Account) at the
time of signing a definitive agreement in connection with the initial Business Combination. However, the Company will only complete a
Business Combination if the post-transaction company owns or acquires 50% or more of the outstanding voting securities of the target
or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment company
under the Investment Company Act.
The Company will provide holders (the “Public Shareholders”)
of its Public Shares, with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination
either (i) in connection with a general meeting called to approve the Business Combination or (ii) by means of a tender offer. The decision
as to whether the Company will seek shareholder approval of a Business Combination or conduct a tender offer will be made by the Company,
solely in its discretion. The Public Shareholders will be entitled to redeem all or a portion of their Public Shares upon the completion
of the initial Business Combination at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust
Account calculated as of two business days prior to the consummation of the initial Business Combination, including interest and other
income earned on the funds held in the Trust Account and not previously released to the Company to pay the Company’s income taxes,
if any, divided by the number of the then-outstanding Public Shares, subject to the limitations described herein. As of September 30,
2023, the amount in the Trust Account was approximately $14.14 per Public Share.
All of the Public Shares contain a redemption
feature which allows for the redemption of such Public Shares in connection with the liquidation, if there is a shareholder vote or tender
offer in connection with the initial Business Combination and in connection with certain amendments to the Company’s memorandum
and articles of association then in existence. In accordance with the Financial Accounting Standards Board’s (“FASB”)
Accounting Standards Codification (“ASC”) Topic 480, “Distinguishing Liabilities from Equity” (“ASC 480”),
paragraph 10-S99, redemption provisions not solely within the control of a company require ordinary shares subject to redemption to be
classified outside of permanent equity. Accordingly, all of the Public Shares are presented as temporary equity, outside of the shareholders’
equity section of the Company’s balance sheet. Given that the Public Shares were issued with other freestanding instruments (i.e.,
public warrants), the initial carrying value of Class A ordinary shares classified as temporary equity was the allocated amount of the
proceeds. If it is probable that the equity instrument will become redeemable, the Company has the option to either (i) accrete changes
in the redemption value over the period from the date of issuance (or from the date that it becomes probable that the instrument will
become redeemable, if later) to the earliest redemption date of the instrument or (ii) recognize changes in the redemption value immediately
as they occur and adjust the carrying amount of the instrument to equal the redemption value at the end of each reporting period. The
Company will elect to recognize the changes in redemption value immediately. The change in redemption value was recognized as a one-time
charge against additional paid-in capital (to the extent available) and accumulated deficit. The Public Shares are redeemable and are
classified as such on the balance sheet until such date that a redemption event takes place. Additionally, each Public Shareholder may
elect to redeem its Public Shares irrespective of whether it votes for or against the proposed transaction or vote at all. If the Company
seeks shareholder approval in connection with a Business Combination, the initial shareholders (as defined below) agreed to vote their
Founder Shares (as defined below in Note 4) and any Public Shares purchased during or after the Initial Public Offering in favor of a
Business Combination.
Notwithstanding the foregoing, the Company’s
second amended and restated memorandum and articles of association (the “Second A&R Articles”) provide that a Public
Shareholder, together with any affiliate of such shareholder or any other person with whom such shareholder is acting in concert or as
a “group” (as defined in Section 13 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)),
will be restricted from redeeming its shares with respect to more than an aggregate of 15% of the shares sold in the Initial Public Offering,
without the prior consent of the Company.
GENESIS GROWTH TECH ACQUISITION CORP.
NOTES TO UNAUDITED FINANCIAL STATEMENTS
Pursuant to the terms of the Company’s
memorandum and articles of association then existing, in order to extend the period of time to consummate an initial Business Combination,
the Sponsor deposited $2,530,000 into the Trust Account on December 9, 2022, for a three-month extension expiring on March 13, 2023.
On February 22, 2023, the shareholders approved an amendment to the amended and restated memorandum and articles of association to
extend the deadline to complete an initial Business Combination from March 13, 2023 to September 13, 2023 (the “Extension Amendment
Proposal”). The Company has until 21 months from the closing of the Initial Public Offering, or September 13, 2023 (the “Combination
Period”), to consummate the initial Business Combination. If the Company is unable to complete a Business Combination within the
Combination Period, the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible
but not more than 10 business days thereafter, redeem the Public Shares, at a per-share price, payable in cash, equal to the aggregate
amount then on deposit in the Trust Account, including interest and other income earned on the funds held in the Trust Account and not
previously released to the Company to pay its income taxes, if any (less up to $100,000 of interest to pay dissolution expenses), divided
by the number of then issued and outstanding Public Shares, which redemption will completely extinguish Public Shareholders’ rights
as shareholders (including the right to receive further liquidation distributions, if any) and (iii) as promptly as reasonably possible
following such redemption, subject to the approval of the remaining shareholders and the board of directors, liquidate and dissolve,
subject in each case to the Company’s obligations under Cayman Islands law to provide for claims of creditors and the requirements
of other applicable law.
In connection with the Extension Amendment Proposal,
shareholders elected to redeem 25,198,961 Class A ordinary shares in the Company, representing approximately 99.6% of the issued and
outstanding Class A ordinary shares in the Company, for a pro rata portion of the funds in the Company’s trust account. As a result,
$263,325,414 (approximately $10.45 per share) was debited from the Company’s trust account to pay such holders.
The Company’s Sponsor, executive
officers, directors and director nominees (the “initial shareholders”) agreed not to propose any amendment to the Second
A&R Articles (A) that would modify the substance or timing of the Company’s obligation to provide holders of the Class A ordinary
shares the right to have their shares redeemed in connection with the Company’s initial Business Combination or to redeem 100%
of its Public Shares if the Company does not complete a Business Combination by September 13, 2023 or (B) with respect to any other provision
relating to the rights of holders of the Class A ordinary shares, unless the Company provides the Public Shareholders with the opportunity
to redeem their Class A ordinary shares upon approval of any such amendment at a per-share price, payable in cash, equal to the aggregate
amount then on deposit in the Trust Account, including interest and other income earned on the funds held in the Trust Account and not
previously released to the Company to pay its income taxes, if any, divided by the number of the then-outstanding Public Shares.
The Sponsor, officers and directors agreed to
waive their liquidation rights with respect to the Founder Shares if the Company fails to complete a Business Combination within the
Combination Period. However, if the initial shareholders or members of the Company’s management team acquire Public Shares in or
after the Initial Public Offering, they will be entitled to liquidating distributions from the Trust Account with respect to such Public
Shares if the Company fails to complete a Business Combination within the Combination Period. The underwriter agreed to waive their rights
to their deferred underwriting commission (see Note 5) held in the Trust Account in the event the Company does not complete a Business
Combination within the Combination Period and, in such event, such amount will be included with the other funds held in the Trust Account
that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the per share
value of the residual assets remaining available for distribution (including Trust Account assets) will be only $10.00 per share initially
held in the Trust Account. In order to protect the amounts held in the Trust Account, the Sponsor has agreed to be liable to the Company
if and to the extent any claims by a vendor for services rendered or products sold to the Company, or a prospective target business with
which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the Trust Account. This liability
will not apply with respect to any claims by a third party who executed a waiver of any right, title, interest or claim of any kind in
or to any monies held in the Trust Account or to any claims under the Company’s indemnity of the underwriter of the Initial Public
Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”).
Moreover, in the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible
to the extent of any liability for such third-party claims. The Company will seek to reduce the possibility that the Sponsor will have
to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers (except for the Company’s
independent registered accounting firm), prospective target businesses or other entities with which the Company does business execute
agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account.
GENESIS GROWTH TECH ACQUISITION CORP.
NOTES TO UNAUDITED FINANCIAL STATEMENTS
On August 31, 2023,
GGAA held a second extraordinary general meeting of shareholders at which holders of 5,883,786 ordinary shares in the Company were present
virtually or by proxy, representing approximately 92% of the voting power of the 6,426,039 ordinary shares issued and outstanding entitled
to vote at the Extraordinary General Meeting at the close of business on August 7, 2023, which was the record date for the Extraordinary
General Meeting. In connection with the Second Extension Amendment Proposal, Shareholders holding an aggregate of 19,519 Class A ordinary
shares of GGAA, representing approximately 0.3% of the issued and outstanding Class A ordinary shares in GGAA, elected to redeem such
shares for a pro rata portion of the funds in GGAA’s trust account. As a result, approximately $246,605.40 (approximately $12.63
per share) was debited from the Company’s trust account to pay such holders. At this meeting shareholders of the Company also proposed
and approved an additional extension proposal extending the timeline in which the Company can consummate a business combination from
September 13, 2023 to December 13, 2024.
Proposed Business Combination and Termination
On August 22, 2022, the Company, and Biolog-ID,
a société anonyme organized under the laws of France (“Biolog-id”), signed a memorandum of understanding
(the “MoU”) with respect to the contemplated merger of the Company with and into Biolog-id (the “Biolog Merger”)
with Biolog-id as the continuing company following closing of the Merger and related transactions pursuant to the Business Combination
Agreement in the form attached to the MoU. Under French law, no commitment with respect to the proposed Biolog Merger could be agreed
prior to Biolog-id completing the consultation process with its social and economic committee (comité social et économique)
(the “Works Council”). Biolog-id completed the Works Council consultation process and on August 26, 2022, the Company and
Biolog-id entered into a Business Combination Agreement (the “BCA”).
By virtue of the Biolog-id Merger, each Company
ordinary share issued and outstanding immediately prior to the effective time of the Biolog Merger (after giving effect to specified
events) would be automatically cancelled and extinguished and exchanged for a number of ordinary shares of Biolog-id (received in the
form of American Depositary Shares), as determined in accordance with the exchange ratio described in the BCA.
Effective March 6, 2023 and in accordance with
Section 7.1(a) of the BCA, the Company and Biolog-id mutually agreed to terminate the BCA, pursuant to a termination agreement by and
between the Company and Biolog-id (the “Termination Agreement”). Under the Termination Agreement, the Company waived and
released all claims, obligations, liabilities and losses against Biolog-id and its Company Non-Party Affiliates (as defined therein),
and Biolog-id waived and released all claims, obligations, liabilities and losses against the Company and its SPAC Non-Party Affiliates
(as defined therein), arising or resulting from or relating to, directly or indirectly, the BCA, any other transaction documents, any
of the transactions contemplated by the BCA or any other transaction documents, except for any terms, provisions, rights or obligations
that expressly survive the termination of the BCA or set forth in the Termination Agreement.
GENESIS GROWTH TECH ACQUISITION CORP.
NOTES TO UNAUDITED FINANCIAL STATEMENTS
Going Concern Consideration
As of September 30, 2023, the Company had a working capital deficit
of approximately $4.8 million.
The Company’s liquidity needs prior to
the consummation of the Initial Public Offering were satisfied through the payment of $25,000 from the Sponsor to cover certain expenses
on behalf of the Company in exchange for issuance of Founder Shares (as defined in Note 4) and a loan from the Sponsor of approximately
$453,000 under the Note (as defined in Note 4). Subsequent to the consummation of the Initial Public Offering, the Company’s liquidity
has been satisfied through the net proceeds from the consummation of the Initial Public Offering and the Private Placement Warrants held
outside of the Trust Account.
In addition, in order to finance transaction
costs in connection with a Business Combination, the Sponsor, members of the Company’s founding team or any of their affiliates
may, but are not obligated to, loan the Company funds under the Working Capital Loans (as defined and described in Note 4) as needed.
However, in connection with the Company’s assessment of going
concern considerations in accordance with FASB Accounting Standards Update (“ASU”) No. 2014-15, “Disclosures of Uncertainties
about an Entity’s Ability to Continue as a Going Concern,” management has determined that the Company’s liquidity needs,
mandatory liquidation and subsequent dissolution raises substantial doubt about the Company’s ability to continue as a going concern.
No adjustments have been made to the carrying amounts of assets or liabilities should the Company be required to liquidate after December
13, 2024. The unaudited financial statements do not include any adjustment that might be necessary if the Company is unable to continue
as a going concern.
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING
POLICIES
Basis of Presentation
The accompanying unaudited financial statements
are presented in U.S. dollars in conformity with accounting principles generally accepted in the United States of America (“U.S.
GAAP”) for interim financial information and pursuant to the rules and regulations of the SEC. Accordingly, certain disclosures
included in the annual financial statements have been or omitted from these financial statements as they are not required for interim
financial statements under U.S. GAAP and the rules of the SEC. In the opinion of management, the accompanying unaudited financial statements
reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results
for the periods presented. Operating results for the three and nine months ended September 30, 2023 are not necessarily indicative of
the results that may be expected through December 31, 2023.
The accompanying unaudited financial statements
should be read in conjunction with the audited financial statements and notes thereto included in the Annual Report on Form 10-K filed
by the Company with the SEC on June 20, 2023. The financial information as of December 31, 2022, is derived from the audited financial
statements presented in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, as filed with the SEC on
June 20, 2023.
Emerging Growth Company
The Company is an “emerging growth company,”
as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”),
and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that
are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements
of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and
proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder
approval of any golden parachute payments not previously approved.
GENESIS GROWTH TECH ACQUISITION CORP.
NOTES TO UNAUDITED FINANCIAL STATEMENTS
Further, Section 102(b)(1) of the JOBS Act exempts
emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that
is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered
under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that an
emerging growth company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging
growth companies but any such an election to opt out is irrevocable. The Company has elected not to opt out of such extended transition
period, which means that when a standard is issued or revised and it has different application dates for public or private companies,
the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised
standard. This may make the comparison of the Company’s unaudited financial statements with those of another public company that
is neither an emerging growth company nor an emerging growth company that has opted out of using the extended transition period difficult
or impossible because of the potential differences in accounting standards used.
Use of Estimates
The preparation of unaudited financial statements
in conformity with U.S. GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts
of assets and liabilities and disclosure of contingent assets and liabilities at the unaudited financial statements and the reported
amounts of expenses during the reporting period. Actual results could differ from those estimates.
Cash and Cash Equivalents
The Company considers all short-term investments with an original maturity
of three months or less when purchased to be cash equivalents. As of September 30, 2023 and December 30, 2022, the Company had $0 in cash
held in an operating bank account.
Investments Held in Trust Account
The Company’s portfolio of investments
held in the Trust Account is comprised of U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment
Company Act, with a maturity of 185 days or less, or investments in money market funds that invest in U.S. government securities and
generally have a readily determinable fair value, or a combination thereof. When the Company’s investments held in the Trust Account
are comprised of U.S. government securities, the investments are classified as trading securities. When the Company’s investments
held in the Trust Account are comprised of money market funds, the investments are recognized at fair value. Trading securities and investments
in money market funds are presented on the balance sheets at fair value at the end of each reporting period. Interest is received through
the issuance of additional U.S. government treasury obligations and recorded as paid-in-kind interest income in the accompanying statements
of operations. The estimated fair values of investments held in the Trust Account are determined using available market information.
The balance shown in the Trust Account at September 30, 2023 and December 31, 2022 is inclusive of $0 and $2,530,000 in cash deposits
related to an extension payment from Sponsor, respectively.
GENESIS GROWTH TECH ACQUISITION CORP.
NOTES TO UNAUDITED FINANCIAL STATEMENTS
Fair Value of Financial Instruments
The fair value of the Company’s assets
and liabilities, which qualify as financial instruments under FASB ASC Topic 820, “Fair Value Measurements,” equal or approximate
the carrying amounts represented in the balance sheets, primarily due to their short-term nature.
Fair Value Measurements
Fair value is defined as the price that would
be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement
date. U.S. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy
gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and
the lowest priority to unobservable inputs (Level 3 measurements). These tiers consist of:
|
● |
Level 1, defined
as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets; |
|
● |
Level 2, defined
as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for
similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and |
|
● |
Level 3, defined
as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such
as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. |
In some circumstances, the inputs used to measure
fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is
categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement.
Derivative Financial Instruments
The Company evaluates its equity-linked financial
instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with
ASC Topic 815, “Derivatives and Hedging” (“ASC 815”). For derivative financial instruments that are classified
as liabilities, the derivative instrument is initially recognized at fair value with subsequent changes in fair value recognized in the
statements of operations each reporting period.
The Company accounted for the 12,650,000 warrants
included in the Units sold in the Initial Public Offering and the 8,875,000 Private Placement Warrants in accordance with the guidance
contained in ASC 815. Such guidance provides that the warrants described above are not precluded from equity classification. Equity-classified
contracts are initially measured at fair value (or allocated value). Subsequent changes in fair value are not recognized as long as the
contracts continue to be classified in equity.
Offering Costs Associated with the Initial
Public Offering
The Company complies with the requirements of
FASB ASC 340-10-S99-1. Offering costs consisted of legal, accounting, underwriting commissions and other costs incurred through the Initial
Public Offering that were directly related to the Initial Public Offering. Deferred underwriting commissions are classified as non-current
liabilities as their liquidation is not reasonably expected to require the use of current assets or require the creation of current liabilities.
GENESIS GROWTH TECH ACQUISITION CORP.
NOTES TO UNAUDITED FINANCIAL STATEMENTS
Class A Ordinary Shares Subject to Possible
Redemption
The Company accounts for its Class A ordinary
shares subject to possible redemption in accordance with the guidance in ASC 480. Class A ordinary shares subject to mandatory redemption
(if any) are classified as liability instruments and are measured at fair value. Conditionally redeemable Class A ordinary shares (including
Class A ordinary shares that feature redemption rights that are either within the control of the holder or subject to redemption upon
the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times,
Class A ordinary shares are classified as shareholders’ deficit. The Company’s Class A ordinary shares feature certain redemption
rights that are considered to be outside of its control and subject to the occurrence of uncertain future events. In connection with
the Extension Amendment Proposal, shareholders elected to redeem 25,198,961 Class A ordinary shares in the Company, representing approximately
99.6% of the issued and outstanding Class A ordinary shares in the Company, for a pro rata portion of the funds in the Company’s
trust account. As a result, $263,325,414 (approximately $10.45 per share) was debited from the Company’s trust account to pay such
holders. Accordingly, as of September 30, 2023 and December 31, 2022, 101,039 and 25,300,000 Class A ordinary shares subject to possible
redemption, respectively are presented as temporary equity, outside of the shareholders’ deficit section of the Company’s
balance sheets.
On August 31, 2023, GGAA held a second extraordinary
general meeting of shareholders at which holders of 5,883,786 ordinary shares in the Company were present virtually or by proxy, representing
approximately 92% of the voting power of the 6,426,039 ordinary shares issued and outstanding entitled to vote at the Extraordinary General
Meeting at the close of business on August 7, 2023, which was the record date for the Extraordinary General Meeting. In connection with
the Second Extension Amendment Proposal, Shareholders holding an aggregate of 19,519 Class A ordinary shares of GGAA, representing approximately
0.3% of the issued and outstanding Class A ordinary shares in GGAA, elected to redeem such shares for a pro rata portion of the funds
in GGAA’s trust account. As a result, approximately $246,605.40 (approximately $12.63 per share) was debited from the Company’s
trust account to pay such holders.
Under ASC 480-10-S99, the Company has to recognize
changes in the redemption value immediately as they occur and adjust the carrying value of the security to equal the redemption value
at the end of each reporting period. This method would view the end of the reporting period as if it were also the redemption date for
the security. Immediately upon the closing of the Initial Public Offering, the Company recognized the accretion from initial book value
to redemption amount. The change in the carrying value of redeemable shares of Class A ordinary shares is treated as a deemed dividend,
which results in charges against additional paid-in capital and accumulated deficit.
The Class A ordinary shares subject to possible
redemption reflected on the accompanying balance sheets are reconciled on the following table:
Class A ordinary shares subject to possible redemption as of December 31, 2022 |
|
|
262,860,151 |
|
Less: |
|
|
|
|
Redemption of ordinary shares |
|
|
(236,572,019 |
) |
Plus: |
|
|
|
|
Increase in redemption value of Class A ordinary shares subject to possible redemption |
|
|
1,864,526 |
|
Class A ordinary shares subject to possible redemption as of September 30, 2023 |
|
$ |
1,152,658 |
|
Net Income (Loss) per Ordinary Share
The Company complies with accounting and disclosure
requirements of FASB ASC Topic 260, “Earnings Per Share.” The Company has two classes of shares, which are referred to as
Class A ordinary shares and Class B ordinary shares. Income and losses are shared pro rata between the two classes of shares, which assumes
a business combination as the most likely outcome. Net income (loss) per ordinary share is calculated by dividing the net income (loss)
by the weighted average number of ordinary shares outstanding for the respective period.
Net income (loss) per ordinary share is computed
by dividing net income (loss) by the weighted average number of ordinary shares outstanding during the period, excluding ordinary shares
subject to forfeiture. The calculation of diluted net income (loss) does not consider the effect of the warrants underlying the Units
sold in the Initial Public Offering (including the consummation of the Over-allotment) and the private placement warrants to purchase
an aggregate of 21,525,000 shares of Class A ordinary shares in the calculation of diluted income (loss) per share, because their inclusion
would be anti-dilutive under the treasury stock method.
GENESIS GROWTH TECH ACQUISITION CORP.
NOTES TO UNAUDITED FINANCIAL STATEMENTS
The tables below present a reconciliation of
the numerator and denominator used to compute basic and diluted net income (loss) per share for each class of ordinary shares:
|
|
For the Three Months Ended September 30, |
|
|
|
2023 |
|
|
2022 |
|
|
|
Class A |
|
|
Class B |
|
|
Class A |
|
|
Class B |
|
Basic and diluted net (loss) income per ordinary share: |
|
|
|
|
|
|
|
|
|
|
|
|
Numerator: |
|
|
|
|
|
|
|
|
|
|
|
|
Allocation of net (loss) income |
|
$ |
(4,542 |
) |
|
$ |
(304,804 |
) |
|
$ |
3,792 |
|
|
$ |
948 |
|
Denominator: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted weighted average ordinary shares outstanding |
|
|
94,250 |
|
|
|
6,325,000 |
|
|
|
25,300,000 |
|
|
|
6,325,000 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted net (loss) income per ordinary share |
|
$ |
(0.05 |
) |
|
$ |
(0.05 |
) |
|
$ |
0.00 |
|
|
$ |
0.00 |
|
|
|
For the Nine Months Ended September 30, |
|
|
|
2023 |
|
|
2022 |
|
|
|
Class A |
|
|
Class B |
|
|
Class A |
|
|
Class B |
|
Basic and diluted net (loss) income per ordinary share: |
|
|
|
|
|
|
|
|
|
|
|
|
Numerator: |
|
|
|
|
|
|
|
|
|
|
|
|
Allocation of net (loss) income |
|
$ |
391,589 |
|
|
$ |
487,256 |
|
|
$ |
(229,339 |
) |
|
$ |
(57,335 |
) |
Denominator: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted weighted average ordinary shares outstanding |
|
|
4,990,857 |
|
|
|
6,325,000 |
|
|
|
25,300,000 |
|
|
|
6,325,000 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted net (loss) income per ordinary share |
|
$ |
0.08 |
|
|
$ |
0.08 |
|
|
$ |
(0.01 |
) |
|
$ |
(0.01 |
) |
Income Taxes
The Company follows the guidance for accounting
for income taxes under FASB ASC 740, “Income Taxes,” which prescribes a recognition threshold and a measurement attribute
for the unaudited financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For
those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities.
There were no unrecognized tax benefits as of September 30, 2023 and December 31, 2022. The Company’s management determined that
the Cayman Islands is the Company’s only major tax jurisdiction. The Company recognizes accrued interest and penalties related
to unrecognized tax benefits as income tax expense. No amounts were accrued for the payment of interest and penalties as of September
30, 2023 and December 31, 2022. The Company is currently not aware of any issues under review that could result in significant payments,
accruals or material deviation from its position.
The Company is considered to be an exempted Cayman
Islands company with no connection to any other taxable jurisdiction and is presently not subject to income taxes or income tax filing
requirements in the Cayman Islands or the United States of America. As such, the Company’s tax provision was zero for the period
presented. There is currently no taxation imposed on income by the Government of the Cayman Islands. In accordance with Cayman Islands
income tax regulations, income taxes are not levied on the Company. Consequently, income taxes are not reflected in the Company’s
unaudited financial statements. The Company’s management does not expect that the total amount of unrecognized tax benefits will
materially change over the next 12 months.
Accounting Pronouncements
In June 2022, the FASB issued ASU No. 2022-03,
ASC Subtopic 820 “Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions.” The ASU amends ASC
820 to clarify that a contractual sales restriction is not considered in measuring an equity security at fair value and to introduce
new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value. The ASU applies
to both holders and issuers of equity and equity-linked securities measured at fair value. The amendments in this ASU are effective for
the Company in fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. Early adoption is permitted
for both interim and annual financial statements that have not yet been issued or made available for issuance. The Company is still evaluating
the impact of this pronouncement on the unaudited financial statements.
GENESIS GROWTH TECH ACQUISITION CORP.
NOTES TO UNAUDITED FINANCIAL STATEMENTS
The Company’s management does not believe
that any other recently issued, but not yet effective, accounting standards updates, if currently adopted, would have a material effect
on the accompanying unaudited financial statements.
NOTE 3 - INITIAL PUBLIC OFFERING
On December 13, 2021, the Company consummated
its Initial Public Offering of 22,000,000 units (the “Units” and, with respect to the Class A ordinary shares included in
the Units being offered, the “Public Shares”), at $10.00 per Unit, generating gross proceeds of $220.0 million, and incurring
offering costs of approximately $19.0 million, of which $12.1 million was for deferred underwriting fees for costs relating to the Initial
Public Offering. On December 21, 2021, the underwriters, pursuant to the full exercise of the over-allotment option, purchased 3,300,000
Units. The over-allotment units were sold at the offering price of $10.00 per Unit, generating additional gross proceeds to the Company
of $33.0 million. The Company incurred additional offering costs of approximately $2.1 million in connection with the over-allotment,
of which approximately $1.8 million was for deferred underwriting commissions (see Note 5).
Each Unit consists of one Class A ordinary share,
par value $0.0001 per share, and one-half of one redeemable warrant (each, a “Public Warrant”). Each whole Public Warrant
entitles the holder to purchase one Class A ordinary share at a price of $11.50 per share, subject to adjustment (see Note 6).
NOTE 4 - RELATED PARTY TRANSACTIONS
Founder Shares
On May 26, 2021, the Sponsor paid $25,000, or
approximately $0.003 per share, to cover certain expenses in consideration for 7,187,500 Class B ordinary shares, par value $0.0001 per
share (the “Founder Shares”). On September 20, 2021, the Sponsor surrendered an aggregate of 1,437,500 Class B ordinary shares
to the Company’s capital for no consideration, and on December 8, 2021, the Sponsor effected a share capitalization, resulting
in the Sponsor holding an aggregate of 6,325,000 Class B ordinary shares. In December 2021, the Sponsor transferred to Nomura Securities
International, Inc. (“Nomura”), the underwriter of the Initial Public Offering, an aggregate of 474,375 Founder Shares at
the Sponsor’s original purchase price of $1,500, subject to forfeiture by Nomura if the Initial Public Offering was terminated
or if Nomura was not the underwriter of the Initial Public Offering. As a result, the Sponsor holds 5,850,625 Founder Shares and Nomura
holds 474,375 Founder Shares. Up to 825,000 Founder Shares were subject to forfeiture to the extent that the over-allotment option is
not exercised in full by the underwriter, so that the Founder Shares would represent 20.0% of the Company’s issued and outstanding
shares after the Initial Public Offering. On December 21, 2021, the underwriters fully exercised the over-allotment option to purchase
an additional 3,300,000 Units. As a result, the 825,000 Founder Shares are no longer subject to forfeiture.
The Company determined that the excess of the
fair value of the Founder Shares acquired by Nomura from the Sponsor over the price paid by Nomura should be recognized as an offering
cost by the Company in accordance with SEC Staff Accounting Bulletin (“SAB”) Topic 5A, “Expenses of Offerings.”
The allocated portion of the additional offering cost associated with the Class A ordinary shares was charged to the carrying value of
Class A ordinary shares subject to possible redemption upon the completion of the Initial Public Offering.
Private Placement Warrants
Simultaneously with the closing of the Initial
Public Offering, the Company consummated the Private Placement of 8,050,000 Private Placement Warrants, at a price of $1.00 per Private
Placement Warrant to the Sponsor, generating proceeds of approximately $8.1 million. In connection with the full exercise of the over-allotment
option on December 21, 2021, the Sponsor purchased an additional 825,000 Private Placement Warrants at a purchase price of $1.00 per
Private Placement Warrant, generating additional gross proceeds to the Company of $800,000, and the remaining $25,000 was a receivable.
This receivable amount was offset against the Note (as defined below).
Each warrant is exercisable to purchase one Class
A ordinary share at $11.50 per share. A portion of the proceeds from the Private Placement Warrants was added to the proceeds from the
Initial Public Offering held in the Trust Account. If the Company does not complete a Business Combination within the Combination Period,
the Private Placement Warrants will expire worthless.
GENESIS GROWTH TECH ACQUISITION CORP.
NOTES TO UNAUDITED FINANCIAL STATEMENTS
The Sponsor and the Company’s officers
and directors agreed, subject to limited exceptions, not to transfer, assign or sell any of their Private Placement Warrants until 30
days after the completion of the initial Business Combination.
Promissory Note - Related Party
The Sponsor agreed to loan the Company up to
$500,000 to cover expenses related to the Initial Public Offering pursuant to a promissory note, dated May 26, 2021, and amended on October
26, 2021, (the “Note”). This loan was non-interest bearing and payable on the earlier of March 31, 2022, or the completion
of the Initial Public Offering. As of the date of the Initial Public Offering, the Company had borrowed approximately $453,000 under
the Note. In December 2021, subsequent to the Initial Public Offering, the Company repaid $200,000 on the Note and also offset the $25,000
receivable related to the Private Placement Warrants against the Note. As a result, as of December 31, 2021, the Company had approximately
$228,000 outstanding on the Note, which was due upon demand. In March 2022, the Company repaid the remaining balance of the Note to the
Sponsor. As of September 30, 2023, the Company had no outstanding balance under the Note.
On December 9, 2022, in connection with the extension
of the deadline for the Company to complete its initial business combination to March 13, 2023, the Sponsor funded an extension payment
for $2,530,000 into the Trust Account. This amount is non-interest bearing and payable on the completion of the Business Combination.
The funds were deposited directly into the trust account. As of September 30, 2023 and December 31, 2022 the balance of the loan was
$2,307,717 and $2,530,000, respectively.
Working Capital Loans
In addition, in order to finance transaction
costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company’s officers
and directors, may, but are not obligated to, loan the Company funds as may be required (“Working Capital Loans”). If the
Company completes a Business Combination, the Company would repay the Working Capital Loans out of the proceeds of the Trust Account
released to it. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside the Trust
Account to repay the Working Capital Loans but no proceeds held in the Trust Account would be used to repay the Working Capital Loans.
The Working Capital Loans would either be repaid upon consummation of a Business Combination, without interest, or, at the lender’s
discretion, up to $1.5 million of such Working Capital Loans may be convertible into warrants of the post Business Combination entity
at a price of $1.00 per warrant. The warrants would be identical to the Private Placement Warrants. Except for the foregoing, the terms
of such Working Capital Loans, if any, have not been determined and no written agreements exist with respect to such loans. As of September
30, 2023 and December 31, 2022, the Company had no borrowings under the Working Capital Loans.
Administrative Support Agreement
On December 8, 2021, the Company entered into
an agreement with the Sponsor, pursuant to which the Company agreed to reimburse the Sponsor for office space, secretarial and administrative
services provided to the Company in the amount of $10,000 per month through the earlier of the consummation of the initial Business Combination
and the Company’s liquidation. For the three and nine months ended September 30, 2023, the Company incurred and accrued expenses
of $30,000 and $90,000, respectively, under this agreement. For the three and nine months ended September 30, 2022, the Company incurred
and accrued expenses of $30,000 and $100,000, respectively, under this agreement. As of September 30, 2023 and December 31, 2022, the
Company had an outstanding balance of $10,000 and $130,000 under this agreement, respectively, which is included in “Accounts payable
and accrued expenses” on the accompanying balance sheets.
Due from Related Party
On June 20, 2023, the Company was paid the $1,057,397
due from related party as of September 30, 2023, in full and the amount owed to the Company was transferred into the Company’s
operating bank account.
As of September 30, 2023 and December 31, 2022,
the Company had a balance of $0 and $1,200,595, respectively, due from a related party to support the Company’s operations. The
balance was unsecured and non-interest bearing.
GENESIS GROWTH TECH ACQUISITION CORP.
NOTES TO UNAUDITED FINANCIAL STATEMENTS
NOTE
5 - COMMITMENTS AND CONTINGENCIES
Registration Rights
The holders of the Founder Shares, Private Placement
Warrants and any warrants that may be issued upon conversion of Working Capital Loans (and any Class A ordinary shares issuable upon
the exercise of the Private Placement Warrants and warrants that may be issued upon conversion of Working Capital Loans) are entitled
to registration rights pursuant to a registration and shareholder rights agreement signed upon the effective date of the Initial Public
Offering. The holders of these securities are entitled to make up to three demands, excluding short form demands, that the Company registers
such securities. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements
filed subsequent to the Company’s completion of the initial Business Combination. However, the registration and shareholder rights
agreement provides that the Company will not permit any registration statement filed under the Securities Act to become effective until
termination of the applicable lock-up periods with respect to such securities. The Company will bear the expenses incurred in connection
with the filing of any such registration statements.
Underwriting Agreement
The underwriter was entitled to an underwriting
discount of $0.10 per Unit, or $2.5 million in the aggregate, paid upon the closing of the Initial Public Offering (including over-allotment).
In addition, $0.55 per unit, or $13.9 million in the aggregate, will be payable to the underwriter for deferred underwriting commissions.
The deferred fee will become payable to the underwriter from the amounts held in the Trust Account solely in the event that the Company
completes a Business Combination, subject to the terms of the underwriting agreement. On January 26, 2023, the underwriter agreed to
waive their rights to their deferred underwriting commission held in the Trust Account in the event the Company does not complete a Business
Combination within in the Combination Period and, in such event, such amount will be included with the other funds held in the Trust
Account that will be available to fund the redemption of the Public Shares.
On January 26, 2023, Nomura Securities International,
Inc. (“Nomura”) the underwriter for the initial public offering of the Company, pursuant to a letter dated as of the same
date, waived its entitlement to the payment of the deferred underwriting discount then payable to Nomura in connection with the initial
public offering and pursuant to the prior underwriting agreement between Nomura and the Company dated December 8, 2021. Other than such
waiver, the letter did not waive any rights or obligations of the Company or Nomura which survive the termination of the underwriting
agreement.
Risks and Uncertainties
Management also continues to evaluate the impact
of the volatility and disruptions in the financial markets caused by, among other things, the ongoing conflict in Ukraine, rising interest
rates and mounting inflationary cost pressures and recessionary fears. The specific impact on the Company’s financial condition,
results of operations, and cash flows is also not determinable as of the date of these unaudited financial statements.
Termination of Previously Planned Merger
Agreement
As previously announced, on May 22, 2023, the
Company., GGAC Merger Sub, Inc., a Florida corporation and newly formed wholly-owned subsidiary of GGAA (“Merger Sub”); NextTrip
Holdings, Inc., a Florida corporation (“NextTrip”); and William Kerby, solely in his capacity as the representative for NextTrip’s
shareholders as discussed in the Plan of Merger entered into an Agreement and Plan of Merger (the “Plan of Merger”) with
the Company.
The Plan of Merger had contemplated that the
Company and NextTrip would engage in a series of transactions pursuant to which, among other transactions, Merger Sub would merge with
and into NextTrip, with NextTrip continuing as the surviving entity upon the closing of the transactions contemplated by the Plan of
Merger, and becoming a wholly-owned subsidiary of the Company.
Effective as of August 16, 2023 and in accordance
with Section 7.1(a) of the Plan of Merger, GGAA and NextTrip mutually agreed to terminate the Plan of Merger, pursuant to the terms of
a termination agreement entered into by and between each of the parties to the Plan of Merger (the “Termination Agreement”).
Additionally, under the Termination Agreement, each of GGAA, Merger Sub and the Purchaser Representative, released NextTrip, the Seller
Representative, and each of their representatives, affiliates, agents and assigns, and each of NextTrip and the Seller Representative
released GGAA, Merger Sub, the Purchaser Representative, and each of their representatives, affiliates, agents and assigns, for any claims,
causes of action, liabilities or damages, except for certain liabilities that survive the termination pursuant to the terms of the Plan
of Merger, or for breaches of the Termination Agreement.
GENESIS GROWTH TECH ACQUISITION CORP.
NOTES TO UNAUDITED FINANCIAL STATEMENTS
NOTE 6 - SHAREHOLDERS’ DEFICIT
Preference shares - The Company
is authorized to issue 5,000,000 preference shares, par value $0.0001 per share, with such designations, voting and other rights and
preferences as may be determined from time to time by the Company’s board of directors. As of September 30, 2023 and December 31,
2022, there were no preference shares issued or outstanding.
Class A Ordinary shares - The Company
is authorized to issue 500,000,000 Class A ordinary shares with a par value of $0.0001 per share. As of September 30, 2023 and December
31, 2022, there were 81,520 and 25,300,000 Class A ordinary shares issued and outstanding, all of which were subject to possible redemption
and were classified outside of permanent equity in the accompanying balance sheets, respectively.
Class B Ordinary shares - The Company
is authorized to issue 50,000,000 Class B ordinary shares with a par value of $0.0001 per share. Holders are entitled to one vote for
each Class B ordinary share. As of September 30, 2023 and December 31, 2022, there were 6,325,000 Class B ordinary shares issued and
outstanding, which amounts have been retroactively restated to reflect the shares surrender on September 20, 2021, and the share capitalization
on December 8, 2021, as discussed in Note 4.
Holders of the Class A ordinary shares and holders
of the Class B ordinary shares will vote together as a single class on all matters submitted to a vote of the Company’s shareholders,
except as required by law or stock exchange rule; provided that only holders of the Class B ordinary shares have the right to vote on
the appointment of the Company’s directors prior to the initial Business Combination.
The Class B ordinary shares will automatically
convert into Class A ordinary shares (which such Class A ordinary shares delivered upon conversion will not have redemption rights or
be entitled to liquidating distributions from the Trust Account if the Company does not consummate an initial Business Combination) at
the time of the Company’s initial Business Combination or earlier at the option of the holders thereof at a ratio such that the
number of Class A ordinary shares issuable upon conversion of all Founder Shares will equal, in the aggregate, on an as-converted basis,
20% of the sum of (i) the total number of ordinary shares issued and outstanding upon completion of our Initial Public Offering, plus
(ii) the total number of Class A ordinary shares issued or deemed issued or issuable upon conversion or exercise of any equity-linked
securities or rights issued or deemed issued, by the Company in connection with or in relation to the consummation of the initial Business
Combination, excluding any Class A ordinary shares, or equity-linked securities exercisable for or convertible into Class A ordinary
shares issued, deemed issued, or to be issued, to any seller in the initial Business Combination and any private placement warrants issued
to the sponsor, its affiliates or any member of the Company’s management team upon conversion of working capital loans (if any).
In no event will the Class B ordinary shares convert into Class A ordinary shares at a rate of less than one-to-one.
Warrants - As of September 30,
2023 and December 31, 2022, 12,650,000 Public Warrants and 8,875,000 Private Placement Warrants were outstanding.
The Public Warrants will become exercisable at
$11.50 per share 30 days after the completion of a Business Combination; provided that the Company has an effective registration statement
under the Securities Act covering the Class A ordinary shares issuable upon exercise of the warrants and a current prospectus relating
to them is available (or the Company permits holders to exercise their warrants on a cashless basis and such cashless exercise is exempt
from registration under the Securities Act). The Company has agreed that as soon as practicable, but in no event later than 15 business
days after the closing of the initial Business Combination, the Company will use commercially reasonable efforts to file with the SEC
a registration statement covering the Class A ordinary shares issuable upon exercise of the warrants. The Company will use its commercially
reasonable efforts to cause the same to become effective within 60 business days after the closing of the initial Business Combination
and to maintain the effectiveness of such registration statement, and a current prospectus relating to those Class A ordinary shares
until the warrants expire or are redeemed, as specified in the warrant agreements; provided that if the Company’s Class A ordinary
shares are at the time of any exercise of a warrant not listed on a national securities exchange such that they satisfy the definition
of a “covered security” under Section 18(b)(1) of the Securities Act, the Company may, at its option, require holders of
Public Warrants who exercise their warrants to do so on a “cashless basis” in accordance with Section 3(a)(9) of the Securities
Act and, in the event the Company so elects, the Company will not be required to file or maintain in effect a registration statement,
but the Company will use its commercially reasonably efforts to register or qualify the shares under applicable blue sky laws to the
extent an exemption is not available. If a registration statement covering the Class A ordinary shares issuable upon exercise of the
warrants is not effective by the 60th day after the closing of the initial Business Combination, warrant holders may, until
such time as there is an effective registration statement and during any period when the Company will have failed to maintain an effective
registration statement, exercise warrants on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act
or another exemption, but the Company will use its commercially reasonably efforts to register or qualify the shares under applicable
blue sky laws to the extent an exemption is not available.
GENESIS GROWTH TECH ACQUISITION CORP.
NOTES TO UNAUDITED FINANCIAL STATEMENTS
The warrants will expire five years after the
completion of a Business Combination or earlier upon redemption or liquidation.
The exercise price and number of shares issuable
upon exercise of the warrants may be adjusted in certain circumstances including in the event of a share dividend or recapitalization,
reorganization, merger or consolidation. In addition, if (x) the Company issues additional Class A ordinary shares or equity-linked securities
for capital raising purposes in connection with the closing of the initial Business Combination at an issue price or effective issue
price of less than $9.20 per Class A ordinary share (with such issue price or effective issue price to be determined in good faith by
the Company’s board of directors and in the case of any such issuance to the Company’s Sponsor or their affiliates, without
taking into account any Founder Shares held by the Company’s Sponsor or such affiliates, as applicable, prior to such issuance
(the “Newly Issued Price”), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity
proceeds, and interest thereon, available for the funding of the initial Business Combination on the date of the consummation of the
initial Business Combination (net of redemptions), and (z) the volume weighted average trading price of the Company’s Class A ordinary
shares during the 20 trading day period starting on the trading day prior to the day on which the Company consummates its initial Business
Combination (such price, the “Market Value”) is below $9.20 per share, then the exercise price of the warrants will be adjusted
(to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, the $18.00 per share redemption
trigger price described below under “Redemption of Warrants When the Price per Class A Ordinary Share Equals or Exceeds $18.00”
will be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price.
Except as described below, the Private Placement
Warrants are identical to those of the warrants being sold as part of the Units in the Initial Public Offering. The Private Placement
Warrants (including the Class A ordinary shares issuable upon exercise of the Private Placement Warrants) will not be transferable, assignable
or salable until 30 days after the completion of the initial Business Combination and they will not be redeemable by the Company. Holders
of the Company’s private placement warrants have the option to exercise the Private Placement Warrants on a cashless basis.
Redemption of Warrants When the Price per
Class A Ordinary Share Equals or Exceeds $18.00
Once the warrants become exercisable, the Company
may call the Public Warrants for redemption (except with respect to the Private Placement Warrants):
|
● |
in whole and
not in part; |
| ● | at a price of $0.01 per warrant; |
| ● | upon a minimum of 30 days’ prior written notice of redemption; and |
| ● | if, and only if, the closing price of the Class A ordinary shares equals or exceeds $18.00 per share for any 20 trading days within a 30-trading day period ending three trading days before the Company sends the notice of redemption to the warrant holders. |
If the Company calls the Public Warrants for
redemption, management will have the option to require all holders that wish to exercise the Public Warrants to do so on a “cashless
basis,” as described in the warrant agreements. Additionally, in no event will the Company be required to net cash settle any Warrants.
If the Company is unable to complete the initial Business Combination within the Combination Period and the Company liquidates the funds
held in the Trust Account, holders of warrants will not receive any of such funds with respect to their warrants, nor will they receive
any distribution from the Company’s assets held outside of the Trust Account with respect to such warrants. Accordingly, the warrants
may expire worthless.
GENESIS GROWTH TECH ACQUISITION CORP.
NOTES TO UNAUDITED FINANCIAL STATEMENTS
NOTE 7 - FAIR VALUE MEASUREMENTS
The Company determines the level in the fair
value hierarchy within which each fair value measurement falls based on the lowest level input that is significant to the fair value
measurement and performs an analysis of the assets and liabilities at each reporting period end.
The following tables present information about
the Company’s financial assets that are measured at fair value on a recurring basis by level within the fair value hierarchy:
September 30, 2023
Description | |
Quoted Prices
in Active
Markets (Level 1) | | |
Significant
Other Observable Inputs (Level 2) | | |
Significant
Other Unobservable Inputs (Level 3) | |
Assets: | |
| | |
| | |
| |
Investments held in Trust Account - Money Market Fund | |
$ | 1,034,847 | | |
$ | — | | |
$ | — | |
December 31, 2022
Description | |
Quoted Prices
in Active
Markets (Level 1) | | |
Significant
Other Observable Inputs (Level 2) | | |
Significant
Other Unobservable Inputs (Level 3) | |
Assets: | |
| | |
| | |
| |
Investments held
in Trust Account - Money Market Fund (1) | |
$ | 262,960,151 | | |
$ | — | | |
$ | — | |
Transfers to/from Levels 1, 2, and 3 are recognized
at the beginning of the reporting period. There were no transfers to/from Levels 1, 2, and 3 during the period from March 17, 2021 (inception)
through September 30, 2023.
Level 1 assets include investments in money market
funds that invest solely in U.S. government securities. The Company uses inputs such as actual trade data, quoted market prices from
dealers or brokers, and other similar sources to determine the fair value of its investments.
NOTE 8 - SUBSEQUENT EVENTS
The Company evaluated subsequent events and transactions
that occurred after the balance sheet date up to the date that the unaudited financial statements were issued. Based upon this review,
the Company did not identify any subsequent events, other than below, that have occurred that would require adjustments to the disclosures
in the accompanying unaudited financial statements.
Item 2. Management’s Discussion and Analysis of Financial Condition
and Results of Operations
References to the “Company,” “Genesis
Growth Tech Acquisition Corp.,” “our,” “us” or “we” refer to Genesis Growth Tech Acquisition
Corp. The following discussion and analysis of the Company’s financial condition and results of operations should be read in conjunction
with the unaudited financial statements and the notes thereto contained elsewhere in this report. Certain information contained in the
discussion and analysis set forth below includes forward-looking statements that involve risks and uncertainties.
In addition, unless the context otherwise requires
and for the purposes of this Report only:
|
● |
“Exchange
Act” refers to the Securities Exchange Act of 1934, as amended; |
|
● |
“SEC”
or the “Commission” refers to the United States Securities and Exchange Commission; and |
|
● |
“Securities
Act” refers to the Securities Act of 1933, as amended. |
This information should be read in conjunction
with the interim unaudited financial statements and the notes thereto included in this Quarterly Report on Form 10-Q, and the audited
financial statements and notes thereto and “Management’s Discussion and Analysis of Financial Condition and Results of Operations”
contained in our Annual Report on Form 10-K for the year ended December 31, 2022, filed with the Securities and Exchange Commission on
June 20, 2023 (the “Annual Report”).
Certain capitalized terms used below and otherwise
defined below, have the meanings given to such terms in the footnotes to our consolidated financial statements included above under “Part
I - Financial Information” – “Item 1. Financial Statements”.
Cautionary Note Regarding Forward-Looking
Statements
This quarterly report on Form 10-Q (this “Report”)
includes forward-looking statements within the meaning of Section 27A of the Securities Act, and Section 21E of the Exchange Act. We
have based these forward-looking statements on our current expectations and projections about future events. These forward-looking statements
are subject to known and unknown risks, uncertainties and assumptions about us that may cause our actual results, levels of activity,
performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed
or implied by such forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,”
“should,” “could,” “would,” “expect,” “plan,” “anticipate,” “believe,”
“estimate,” “continue,” or the negative of such terms or other similar expressions. Factors that might cause
or contribute to such a discrepancy include, but are not limited to, those described in our other SEC filings. We undertake no obligation
to revise or publicly release the results of any revision to any forward-looking statements, except as required by law. Given these risks
and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements.
Overview
We are a blank check company incorporated on
March 17, 2021 as a Cayman Islands exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase,
reorganization or similar business combination with one or more businesses or entities. We intend to effectuate our initial Business
Combination using cash from the proceeds of our Initial Public Offering and the private placement of the Private Placement Warrants,
the proceeds of the sale of our shares in connection with our initial Business Combination (pursuant to forward purchase agreements or
backstop agreements we may enter into), shares issued to the owners of the target, debt issued to bank or other lenders or the owners
of the target, or a combination of the foregoing or other sources.
The issuance of additional shares in a business
combination:
|
● |
may significantly dilute
the equity interest of investors in our Initial Public Offering, which dilution would increase if the anti-dilution provisions in
the Class B ordinary shares resulted in the issuance of Class A ordinary shares on a greater than one-to-one basis upon conversion
of the Class B ordinary shares; |
|
● |
may subordinate the rights
of holders of Class A ordinary shares if preference shares are issued with rights senior to those afforded our Class A ordinary shares; |
|
● |
could cause a change in
control if a substantial number of our Class A ordinary shares are issued, which may affect, among other things, our ability to use
our net operating loss carry forwards, if any, and could result in the resignation or removal of our present officers and directors; |
|
● |
may have the effect of
delaying or preventing a change of control of us by diluting the share ownership or voting rights of a person seeking to obtain control
of us; |
|
● |
may adversely affect prevailing
market prices for our units, Class A ordinary shares and/or warrants; and |
|
● |
may not result in adjustment
to the exercise price of our warrants. |
Similarly, if we issue debt or otherwise incur
significant debt, it could result in:
|
● |
default and foreclosure
on our assets if our operating revenues after an initial business combination are insufficient to repay our debt obligations; |
|
● |
acceleration of our obligations
to repay the indebtedness even if we make all principal and interest payments when due if we breach certain covenants that require
the maintenance of certain financial ratios or reserves without a waiver or renegotiation of that covenant; |
|
● |
our immediate payment of
all principal and accrued interest, if any, if the debt is payable on demand; |
|
● |
our inability to obtain
necessary additional financing if the debt contains covenants restricting our ability to obtain such financing while the debt is
outstanding; |
|
● |
our inability to pay dividends
on our Class A ordinary shares; |
|
● |
using a substantial portion
of our cash flow to pay principal and interest on our debt, which will reduce the funds available for dividends on our Class A ordinary
shares if declared, expenses, capital expenditures, acquisitions and other general corporate purposes; |
|
● |
limitations on our flexibility
in planning for and reacting to changes in our business and in the industry in which we operate; |
|
● |
increased vulnerability
to adverse changes in general economic, industry and competitive conditions and adverse changes in government regulation; and |
|
● |
limitations on our ability
to borrow additional amounts for expenses, capital expenditures, acquisitions, debt service requirements, execution of our strategy
and other purposes and other disadvantages compared to our competitors who have less debt. |
As indicated in the accompanying unaudited financial
statements, as of September 30, 2023, we had a working capital deficit of approximately $3.8 million. Further, we expect to incur significant
costs in the pursuit of our initial business combination. We cannot assure you that our plans to raise capital or to complete our initial
business combination will be successful.
Recent Developments
Extraordinary General Meeting
On August 31, 2023,
GGAA held a second extraordinary general meeting of shareholders at which holders of 5,883,786 ordinary shares in the Company were present
virtually or by proxy, representing approximately 92% of the voting power of the 6,426,039 ordinary shares issued and outstanding entitled
to vote at the Extraordinary General Meeting at the close of business on August 7, 2023, which was the record date for the Extraordinary
General Meeting. In connection with the Second Extension Amendment Proposal, Shareholders holding an aggregate of 19,519 Class A ordinary
shares of GGAA, representing approximately 0.3% of the issued and outstanding Class A ordinary shares in GGAA, elected to redeem such
shares for a pro rata portion of the funds in GGAA’s trust account. As a result, approximately $246,605.40 (approximately $12.63
per share) was debited from the Company’s trust account to pay such holders. At this meeting shareholders of the Company also proposed
and approved an additional extension proposal extending the timeline in which the Company can consummate a business combination from
September 13, 2023, to December 13, 2024.
Termination of Previously Planned Merger
Agreement
As previously announced, on May 22, 2023, the
Company, GGAC Merger Sub, Inc., a Florida corporation and newly formed wholly-owned subsidiary of GGAA (“Merger Sub”); NextTrip
Holdings, Inc., a Florida corporation (“NextTrip”); and William Kerby, solely in his capacity as the representative for NextTrip’s
shareholders as discussed in the Plan of Merger entered into an Agreement and Plan of Merger (the “Plan of Merger”) with
the Company.
The Plan of Merger had contemplated that the
Company and NextTrip would engage in a series of transactions pursuant to which, among other transactions, Merger Sub would merge with
and into NextTrip, with NextTrip continuing as the surviving entity upon the closing of the transactions contemplated by the Plan of
Merger, and becoming a wholly-owned subsidiary of the Company
Effective as of August 16, 2023 and in accordance
with Section 7.1(a) of the Plan of Merger, GGAA and NextTrip mutually agreed to terminate the Plan of Merger, pursuant to the terms of
a termination agreement entered into by and between each of the parties to the Plan of Merger (the “Termination Agreement”).
Additionally, under the Termination Agreement, each of GGAA, Merger Sub and the Purchaser Representative, released NextTrip, the Seller
Representative, and each of their representatives, affiliates, agents and assigns, and each of NextTrip and the Seller Representative
released GGAA, Merger Sub, the Purchaser Representative, and each of their representatives, affiliates, agents and assigns, for any claims,
causes of action, liabilities or damages, except for certain liabilities that survive the termination pursuant to the terms of the Plan
of Merger, or for breaches of the Termination Agreement.
Results of Operations
Our entire activity since inception up to September
30, 2023, was in preparation for our formation and our Initial Public Offering, and, subsequent to our Initial Public Offering, identifying
a target company for a Business Combination. We will not be generating any operating revenues until the closing and completion of our
initial Business Combination, at the earliest.
For the three months ended September 30, 2023,
we had net loss of approximately $309,000, which consisted of general and administrative expenses of $295,000 and $30,000 in general
and administrative expenses for related party, relating to the December 8, 2021 agreement entered into with the Sponsor, pursuant to
which the Company agreed to reimburse the Sponsor for office space, secretarial and administrative services provided to the Company in
the amount of $10,000 per month through the earlier of the consummation of the initial Business Combination and the Company’s liquidation,
offset by income from investments held in the Trust Account of approximately $15,000.
For the three months ended September 30, 2022, we had a net income
of approximately $4,700, which consisted of income from investments held in the Trust Account of approximately $1,136,000, offset by general
and administrative expenses of approximately $1,102,000 and approximately $30,000 in general and administrative expenses for related party.
For the nine months ended September 30, 2023, we had net income of
approximately $879,000, which consisted of income from investments held in the Trust Account of approximately $1,647,000, offset by general
and administrative expenses of approximately $678,000 and $90,000 in general and administrative expenses for related party, relating
to the December 8, 2021 agreement entered into with the Sponsor, pursuant to which the Company agreed to reimburse the Sponsor for office
space, secretarial and administrative services provided to the Company in the amount of $10,000 per month through the earlier of the consummation
of the initial Business Combination and the Company’s liquidation.
For the nine months ended September 30, 2022, we had a net loss of
approximately $287,000, which consisted of general and administrative expenses of approximately $1,686,000 and $90,000 in general and
administrative expenses for related party, offset by income from investments held in the Trust Account of approximately $1,489,000.
Liquidity and Capital Resources
At September 30, 2023, we have $0 cash and a working capital deficit
of $4,867,784.
For the nine months ended September 30,
2023, we had net cash used in operating activities of $978,312, compared to $855,718 for the nine months ended September 30, 2022,
which for the 2023 period was mainly due to $1,646,715 of paid-in-kind interest income on investments held in the trust account and
$878,845 of net income and $210,442 for other operating activities for the 2022 period was mainly due to $286,674 of net loss,
offset by paid-in-kind interest income on investments held in the trust account of $1,489,289 And $920,245 in other operating activities.
We had net cash provided by
investing activities of $264,772,614 for the nine months ended September 30, 2023, compared to $986,995 for the nine months ended
September 30, 2022, which for the 2023 period was mainly due to $263,572,019 of cash withdrawn from the trust account in connection
with redemptions and 2022 was due for $986,995 operating expenses being paid by a related party.
We had $263,794,302 of net cash used in financing activities for the nine months ended September 30, 2023,
compared to $131,277 for the nine months ended September 30, 2022, which for the 2023 period was solely due to the redemption of
ordinary shares and for the 2022 period was solely due to repayment of note payable to related party.
Prior to the completion of our Initial Public
Offering, our liquidity needs were satisfied through (i) $25,000 paid by our Sponsor to cover certain expenses in exchange for the issuance
of the Founder Shares to our Sponsor and (ii) the receipt of a loan of up to $500,000 from our Sponsor under the Note. Prior to the completion
of our Initial Public Offering, we borrowed approximately $453,000 under the Note, which was fully repaid in March 2022. The net proceeds
from (i) the sale of the units in our Initial Public Offering, after deducting non-reimbursed offering expenses of approximately $738,000,
underwriting commissions of $2,530,000, and (ii) the sale of the Private Placement Warrants for a purchase price of $8,875,000, was $258,645,000.
Of that amount, $257,148,600 was initially placed in the Trust Account. In connection with the Extension EGM and as a result of the redemption
of public shares by our public shareholders, approximately $1.2 million remained in the Trust Account as of September 30, 2023. The proceeds
held in the Trust Account are invested only in U.S. government treasury obligations with a maturity of 185 days or less or in money market
funds meeting certain conditions under Rule 2a-7 under the Investment Company Act which invest only in direct U.S. government treasury
obligations.
We intend to use substantially all of the funds
held in the Trust Account, including any amounts representing interest and other income earned on the Trust Account (less taxes payable),
to complete our initial Business Combination. We may withdraw interest income (if any) to pay income taxes, if any. Our annual income
tax obligations will depend on the amount of interest and other income earned on the amounts held in the Trust Account. We expect the
interest income earned on the amount in the Trust Account (if any) will be sufficient to pay our income taxes. To the extent that our
equity or debt is used, in whole or in part, as consideration to complete our initial Business Combination, the remaining proceeds held
in the Trust Account will be used as working capital to finance the operations of the target business or businesses, make other acquisitions
and pursue our growth strategies.
Prior to the completion of our initial Business
Combination, we have available to us the $689,047 of proceeds held outside the Trust Account, as well as certain funds from loans from
our Sponsor, its affiliates or members of our management team. We plan to primarily use these funds to work to complete and close the
Merger.
We do not believe we will need to raise additional
funds to meet the expenditures required for operating our business prior to our initial Business Combination, other than funds available
from loans from our Sponsor, its affiliates or members of our management team. However, if our estimates of the costs of completing the
Merger are less than the actual amount necessary to do so, we may have insufficient funds available to operate our business prior to
our initial Business Combination. In order to fund working capital deficiencies or finance transaction costs in connection with any intended
initial Business Combination, our Sponsor or an affiliate of our Sponsor or certain of our officers and directors may, but are not obligated
to, loan us funds. If we complete our initial Business Combination, we may repay such loaned amounts out of the proceeds of the Trust
Account released to us. In the event that our initial Business Combination does not close, we may use a portion of the working capital
held outside the Trust Account to repay such loaned amounts but no proceeds from our Trust Account would be used for such repayment.
Up to $1,500,000 of such loans may be convertible into warrants of the post-Business Combination entity at a price of $1.00 per warrant
at the option of the lender. The warrants would be identical to the Private Placement Warrants. The terms of such loans, if any, have
not been determined and no written agreements exist with respect to such loans. Prior to the completion of our initial Business Combination,
we do not expect to seek loans from parties other than our Sponsor, its affiliates or our management team as we do not believe third
parties will be willing to loan such funds and provide a waiver against any and all rights to seek access to funds in our Trust Account.
We expect our primary liquidity requirements
during that period to include approximately $300,000 for legal, accounting, due diligence, travel and other expenses associated with
structuring, negotiating and documenting successful business combinations; $100,000 for legal and accounting fees related to regulatory
reporting obligations; $800,000 for directors and officers insurance premiums; $120,000 for office space, administrative and support
services; $100,000 for Nasdaq and other regulatory fees; and $430,000 for general working capital that will be used for miscellaneous
expenses and reserves. These amounts are estimates and may differ materially from our actual expenses.
As a result of our public shareholders electing
to exercise their redemption rights for approximately 99.6% of our public shares in connection with the Extension EGM, we will need to
obtain additional financing to complete our initial Business Combination, in which case we may issue additional securities or incur debt
in connection with such Business Combination. If we have not consummated our initial Business Combination by September 13, 2023, because
we do not have sufficient funds available to us, we will be forced to cease operations and liquidate the Trust Account. The Company currently
expects to hold another extraordinary general meeting of shareholders to seek approval from our public shareholders to further extend
the date by which we have to consummate a business combination, provided that no definitive plans regarding a further extension have
been agreed to by the Board of Directors, and any further extension may not be approved by shareholders.
Based on the foregoing, we believe that we will
have sufficient working capital and borrowing capacity from the Sponsor or an affiliate of the Sponsor, or certain of our officers and
directors to meet our needs through the consummation of a Business Combination. However, in connection with our assessment of going concern
considerations in accordance with Financial Accounting Standards Board’s (“FASB”) Accounting Standards Update (“ASU”)
2014-15, “Disclosures of Uncertainties about an Entity’s Ability to Continue as a Going Concern,” we have determined
that liquidity needs, the mandatory liquidation and subsequent dissolution raises substantial doubt about our ability to continue as
a going concern. No adjustments have been made to the carrying amounts of assets or liabilities should we be required to liquidate after
September 13, 2023. The unaudited financial statements do not include any adjustment that might be necessary if we are unable to continue
as a going concern.
The underwriter of our Initial Public Offering,
Nomura, was entitled to an underwriting discount of $0.10 per Unit, or $2.5 million in the aggregate (including over-allotment), of which
$2.2 million was paid upon the closing of the Initial Public Offering and $0.3 million was paid upon the exercise of the over-allotment
option. In addition, $0.55 per unit, or $13.9 million in the aggregate, was to be payable to Nomura for deferred underwriting commissions.
On January 26, 2023, Nomura waived its right to receive such $13.9 million of deferred underwriting commissions.
Critical Accounting Policies and Estimates
This management’s discussion and analysis
of our financial condition and results of operations is based on our unaudited financial statements, which have been prepared in accordance
with accounting principles generally accepted in the United States of America. The preparation of our unaudited financial statements
requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, income and expenses and the disclosure
of contingent assets and liabilities in our unaudited financial statements. On an ongoing basis, we evaluate our estimates and judgments,
including those related to fair value of financial instruments and accrued expenses. We base our estimates on historical experience,
known trends and events and various other factors that we believe to be reasonable under the circumstances, the results of which form
the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.
Actual results may differ from these estimates under different assumptions or conditions.
Recent Accounting Pronouncements
In June 2022, the FASB issued Accounting Standards
Update (“ASU”) 2022-03, ASC Subtopic 820 “Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions.”
The ASU amends ASC 820 to clarify that a contractual sales restriction is not considered in measuring an equity security at fair value
and to introduce new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair
value. The ASU applies to both holders and issuers of equity and equity-linked securities measured at fair value. The amendments in this
ASU are effective for the Company in fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. Early
adoption is permitted for both interim and annual financial statements that have not yet been issued or made available for issuance.
The Company is still evaluating the impact of this pronouncement on the unaudited financial statements.
Our management does not believe that any other
recently issued, but not yet effective, accounting standards updates, if currently adopted, would have a material effect on the accompanying
unaudited financial statements.
JOBS Act
The Jumpstart Our Business Startups Act of 2012
(the “JOBS Act”) contains provisions that, among other things, relax certain reporting requirements for qualifying public
companies. We qualify as an “emerging growth company” and under the JOBS Act are allowed to comply with new or revised accounting
pronouncements based on the effective date for private (not publicly traded) companies. We are electing to delay the adoption of new
or revised accounting standards, and as a result, we may not comply with new or revised accounting standards on the relevant dates on
which adoption of such standards is required for non-emerging growth companies. As a result, the unaudited financial statements may not
be comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates.
Additionally, we are in the process of evaluating
the benefits of relying on the other reduced reporting requirements provided by the JOBS Act. Subject to certain conditions set forth
in the JOBS Act, if, as an “emerging growth company,” we choose to rely on such exemptions we may not be required to, among
other things, (i) provide an auditor’s attestation report on our system of internal controls over financial reporting pursuant
to Section 404, (ii) provide all of the compensation disclosure that may be required of non-emerging growth public companies under the
Dodd-Frank Wall Street Reform and Consumer Protection Act, (iii) comply with any requirement that may be adopted by the PCAOB regarding
mandatory audit firm rotation or a supplement to the auditor’s report providing additional information about the audit and the
financial statements (auditor discussion and analysis) and (iv) disclose certain executive compensation related items such as the correlation
between executive compensation and performance and comparisons of the CEO’s compensation to median employee compensation. These
exemptions will apply for a period of five years following the completion of our Initial Public Offering or until we are no longer an
“emerging growth company,” whichever is earlier.
Item 3. Quantitative and Qualitative Disclosures About Market Risk
We are a smaller reporting company as defined
by Rule 12b-2 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and are not required to provide the information
otherwise required under this item.
Item 4. Controls and Procedures
Evaluation of Disclosure Controls and Procedures
Disclosure controls and procedures are controls
and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the
Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure
controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed
in company reports filed or submitted under the Exchange Act is accumulated and communicated to management, including our Chief Executive
Officer, Chief Financial Officer and Chief Strategy Officer (“Management”), to allow timely decisions regarding required
disclosure.
As required by Rules 13a-15(e) and 15d-15(e)
under the Exchange Act, Management carried out an evaluation of the effectiveness of the design and operation of our disclosure controls
and procedures as of September 30, 2023. Based upon their evaluation, Management concluded that our disclosure controls and procedures
were not effective as of September 30, 2023, due to the material weaknesses in our internal control over financial reporting of the Company’s
Cash accounts and Due from related party accounts from a failure to segregate bank accounts.
Limitations on Effectiveness of Controls
and Procedures
In designing and evaluating the disclosure controls
and procedures, Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable
assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the
fact that there are resource constraints and that management is required to apply its judgment in evaluating the benefits of possible
controls and procedures relative to their costs.
Changes in Internal Control over Financial
Reporting
In light of the events described above, in the
quarter ended September 30, 2023, we implemented additional control measures to enhance the approval process in connection with our SEC
filings and committed to incorporate as appropriate other training and remedial measures. The elements of our remediation plan can only
be accomplished over time, and we can offer no assurance that these initiatives will ultimately have the intended effects.
Other than as discussed above, there were no
changes in our internal control over financial reporting during the three and nine months ended September 30, 2023, that have materially
affected or are reasonably likely to materially affect, our internal control over financial reporting, including any corrective actions
regarding significant deficiencies and material weaknesses.
PART II. OTHER INFORMATION
Item 1. Legal Proceedings
Although we may, from time to time, be involved
in litigation and claims arising out of our operations in the normal course of business, we are not currently a party to any material
legal proceeding. In addition, we are not aware of any material legal or governmental proceedings against us or contemplated to be brought
against us.
Item 1A. Risk Factors
There have been no material changes from the
risk factors previously disclosed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, filed with
the Commission on June 20, 2023 (the “Form 10-K”), under the heading “Item 1A. Risk Factors”, other than as described
below, and investors are encouraged to review such risk factors in the Form 10-K and below, prior to making an investment in the Company.
Any of these factors, in whole or in part, could materially and adversely affect the Company’s business, financial condition, operating
results and stock price.
We are a foreign private issuer within
the meaning of the rules under the Exchange Act, and as such, we are exempt from certain provisions applicable to U.S. domestic issuers.
Because we qualify as a foreign private issuer
under the Exchange Act, we are exempt from certain provisions of the securities rules and regulations in the United States that are applicable
to U.S. domestic issuers, including:
|
● |
the rules under the Exchange
Act requiring the filing with the SEC of quarterly reports on Form 10-Q or current reports on Form 8-K; |
|
● |
the sections of the Exchange
Act regulating the solicitation of proxies, consents, or authorizations in respect of a security registered under the Exchange Act; |
|
● |
the sections of the Exchange
Act requiring insiders to file public reports of their stock ownership and trading activities and liability for insiders who profit
from trades made in a short period of time; and |
|
● |
the selective disclosure
rules by issuers of material nonpublic information under Regulation FD. |
Irrespective of the above, we have elected to
file, and have filed, an annual report on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K, similar to U.S.
domestic reporting companies.
As a Cayman Islands exempted company and
foreign private issuer within the meaning of the rules under the Exchange Act, we have adopted certain home country practices in relation
to corporate governance matters that differ significantly from the Nasdaq corporate governance listing standards. These practices may
afford less protection to shareholders than they would enjoy if we complied fully with the Nasdaq corporate governance listing standards.
As a Cayman Islands exempted company listed on
the Nasdaq, we are subject to the Nasdaq corporate governance listing standards. However, the Nasdaq permits a foreign private issuer
like us to follow the corporate governance practices of its home country. Certain corporate governance practices in the Cayman Islands,
which is our home country, may differ significantly from the Nasdaq corporate governance listing standards. For instance, we are not
required to:
|
● |
have a majority of the
board be independent or have an audit committee be comprised of three members (although all of the members of the audit committee
must be independent under the Exchange Act); |
|
● |
have a compensation committee
or a nominations or corporate governance committee consisting entirely of independent directors; or |
|
● |
have regularly scheduled
executive sessions with only independent directors each year. |
On November 9, 2022, we filed a Form 8-K with
the SEC announcing the resignations of (i) Mr. Pierre Etienne Lallia and Mr. Massimo Prelz-Oltramonti as board members and (ii) Mr. Simon
Baker as a board member (including his position as Co-Executive Chairman of the board) and our Chief Operating Officer and Executive
Head of M&A. Mr. Lallia and Mr. Prelz-Oltramonti each served on the board’s Audit Committee with Mr. Prelz-Oltramonti also
serving on the board’s Compensation Committee and Nominating Committee. The decisions of Mr. Lallia, Mr. Prelz-Oltramonti and Mr.
Baker to resign as, as applicable, our director and/or executive officer, was not the result of any dispute or disagreement with us on
any matter relating to our operation, policies or practices.
Following these resignations our board is comprised
of three members, including one independent director—Mr. Cem Habib. Mr. Habib serves as the sole member of the Audit, Compensation
and Nominating Committees and he has been designated as the Audit Committee’s financial expert.
Initially, we sought to generally comply with
the general Nasdaq corporate governance listing standards applicable to U.S. domestic issuers. However, in light of the above resignations
and to ensure continued compliance with Nasdaq’s corporate governance rules, we have adopted the following home country practices
in accordance with Nasdaq Listing Rule 5615(a)(3):
|
● |
Audit Committee: As a foreign
private issuer we are required to have an Audit Committee meeting the requirements of Listing Rules 5605(c)(3) and 5605(c)(2)(A)(ii).
Listing Rule 5605(c)(3) requires the Audit Committee to have specified authority and responsibilities and Listing Rule 5605(c)(2)(A)(ii)
requires each member to meet the requisite independence standards but neither requires that the Audit Committee have more than one
member; however, we intend to add at least one additional Audit Committee member meeting the requisite independence standards. |
|
● |
Compensation Committee:
Rule 5615(a)(3) exempts foreign private issuers from all Compensation Committee requirements, including the requirement that Compensation
Committee have at least two independent directors each of whom meets the requisite independence standards; however, we intend to
maintain our Compensation Committee and add an additional member meeting the requisite independence standards. |
|
● |
Majority Independent Directors:
Subject to possible changes in Board composition, we are relying on the provisions of Listing Rule 5615(a)(3) to exempt us from the
requirement that on or after December 13, 2022 (the one-year anniversary of our Initial Public Offering) a majority of our Board
be comprised of independent directors. |
We may be unable to add additional qualified
directors to our board as contemplated above on a timely basis or at all. Accordingly, our shareholders may be afforded less protection
than they otherwise would enjoy under the Nasdaq corporate governance listing standards applicable to U.S. domestic issuers.
Certain special purpose acquisition companies
(SPACs) with small public floats, including the Company, have recently experienced extreme volatility that was seemingly unrelated to
the underlying performance and prospects of the respective companies. We may experience similar volatility in the future, which may make
it difficult for prospective investors to assess the value of our securities.
Our Class A ordinary shares and units recently
experienced extreme volatility that was seemingly unrelated to our financial results and prospects. On July 13, 2023, the trading price
of our Class A ordinary shares, traded between $12.00 and $48.99 per share and the trading price of our units traded between $13.00 and
$37.00 per unit, for reasons unknown. The trading prices of certain other SPACs with small public floats also experienced extreme volatility
and significant increases in trading values for seemingly unknown reasons. The trading price of our securities is likely to continue
to be volatile, and our securities have been, and may continue to be, subject to rapid and substantial price volatility. Such volatility,
including any stock-run up, has, and in the future, may be, unrelated to our actual or expected operating performance, financial condition
or prospects, making it difficult for prospective investors to assess the rapidly changing value of our securities. There have been recent
instances of extreme stock price run-ups followed by rapid price declines, particularly among companies with relatively smaller public
floats, and we expect that such instances may continue and/or increase in the future. Contributing to this risk of volatility are a number
of factors. First, our securities are likely to be more sporadically and thinly traded than that of larger, more established companies.
As a consequence of this lack of liquidity, the trading of relatively small quantities of securities by our securityholders may disproportionately
influence the price of those securities in either direction, which may cause the price of our securities to deviate, potentially significantly,
from a price that better reflects the underlying performance of our business. The price of our securities could, for example, decline
precipitously in the event that a large number of our securities are sold in the market without commensurate demand as compared to a
seasoned issuer that could better absorb those sales without an adverse impact on its security price. Second, we are a speculative investment
due to our status as a SPAC and our business plan to complete a business combination. Third, we have an extremely small float, with only
88,502 outstanding Class A ordinary shares (when not including shares which are part of units) and only 12,537 outstanding units. As
a result, orders to purchase or sell even small numbers of our Series A ordinary shares or units may have an extreme effect on the price
of our securities, due to the small number of shares available for purchase and sale, and may result in extreme volatility which is unrelated
to the underlying performance and prospects of the Company. As a consequence of this enhanced risk, more risk-adverse investors may,
under the fear of losing all or most of their investment in the event of negative news or lack of progress, be more inclined to sell
their securities on the market more quickly and at greater discounts than would be the case with the stock of a larger, more established
company that has a relatively large public float.
Many of these factors are beyond our control
and may decrease the market price of our securities. Such volatility, including any stock run-ups, may be unrelated or disproportionate
to our actual or expected operating performance and financial condition or prospects, making it difficult for prospective investors to
assess the rapidly changing value of our shares.
Furthermore, the stock market in general, and
the market for SPACs in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate
to the operating performance or prospects of those companies. Broad market and industry factors, as well as general economic, political
and market conditions such as recessions, or changes in inflation or interest rates, may seriously affect the market price of our securities,
regardless of our actual operating performance or prospects. These fluctuations may be even more pronounced in the trading market for
our securities as we approach the closing date of a potential business combination, and as a result of our extremely limited public float
as discussed above. As a result of this volatility, investors may experience losses on their investment in our securities. No assurance
can be given that an active market in our securities will develop or be sustained. If an active market does not develop, holders of our
securities may be unable to readily sell the securities they hold or may not be able to sell their securities at all. The price of our
securities may decline in the future and any investment in the Company may be lost.
Our securities are currently subject to
a trading halt with the Nasdaq Global Market and Nasdaq has provided us notice that it plans to delist our securities from Nasdaq.
On July 13, 2023, the Nasdaq Global Market initiated
a trading halt on our Series A ordinary shares, units and warrants in connection with the request by Nasdaq for additional information
regarding our public float and compliance with certain other of Nasdaq’s continued listing requirements (the “Trading
Halt”).
We originally qualified for listing on the Nasdaq
Global Market under Nasdaq that qualified for listing under Nasdaq Rule 5406, which provides for alternative initial listing requirements
for companies whose business plan is to complete one or more acquisitions. In connection therewith, we are required to meet certain continued
listing requirements under Nasdaq Rule 5452. Rule 5452 requires SPACs to meet certain requirements, and including that until a company
has consummated its business combination, Nasdaq will initiate suspension and delisting procedures if: over 30 consecutive trading days
the SPAC’s average market value of listed securities is below $50 million or if the average market value of publicly held shares
is below $40 million. We are also required pursuant to Rule 5452 to maintain (a) at least 300 public stockholders (if a component of
a unit is a warrant, at least 100 holders); (b) at least 1,200 total stockholders and average monthly trading volume of 100,000 shares
(for the most recent 12 months); or (c) at least 600,000 publicly held shares.
On July 14, 2023, we received a written notice
from the Listing Qualifications Department of The Nasdaq Stock Market indicating that our securities (units, ordinary shares and warrants)
will be suspended from The Nasdaq Global Market on July 25, 2023, due to the Company’s non-compliance with Listing Rule 5452. Pursuant
to the July 14, 2023, notice, Nasdaq advised the Company that for the 30 consecutive trading days ending June 27, 2023, the Company’s
average market value of listed securities has been below $50 million and the average market value of publicly held securities for its
Class A ordinary shares has been below $40 million, and as a result, Nasdaq has determined to delist the Company’s securities.
Additionally, in accordance with Nasdaq Listing
Rule 5452(a)(2)(C), SPACs are required to hold at least 600,000 in publicly held shares. According to the Company’s Form 10-K for
the year ended December 31, 2022, Nasdaq calculated the publicly held shares as 101,039. Nasdaq advised that this deficiency serves as
an additional and separate basis for delisting.
Furthermore, as previously disclosed, on May
23, 2023, Nasdaq notified the Company that it did not comply with Listing Rule 5250(c), due to its failure to timely file its Form 10-Q
for the period ended September 30, 2023. The Company’s failure to timely file its periodic report also serves as an additional
and separate basis for delisting; provided that such Form 10-Q has now been filed.
Accordingly, and pursuant to Listing Rule 5815(a)(1)(B)(ii)(c),
unless the Company requests an appeal of this determination, trading of the Company’s listed securities will be suspended from
The Nasdaq Global Market on July 25, 2023, and a Form 25-NSE will be filed with the Securities and Exchange Commission, which will remove
the Company’s securities from listing and registration on The Nasdaq Stock Market.
The Company may appeal Nasdaq’s determination
to a Hearings Panel, pursuant to the procedures set forth in the Nasdaq Listing Rule 5800 Series. Requests for a hearing are required
to be submitted electronically through the Nasdaq Listing Center, and must be received no later than 4:00 Eastern Time on July 21, 2023. The
Company is currently determining whether or not to appeal Nasdaq’s determination. In the event the Company does not appeal Nasdaq’s
determination, the Company expects that its securities (units, ordinary shares and warrants) will be eligible to be quoted on the OTC
Markets.
It is currently unclear whether the Trading Halt
will be lifted by Nasdaq prior to the delisting of the Company’s securities from Nasdaq and/or prior to any determination by a
Hearings Panel, in the event the Company determines to appeal such determination to a Hearings Panel.
Delisting from Nasdaq will likely make trading
our securities more difficult for investors, potentially leading to declines in our trading prices and liquidity. Without a Nasdaq listing,
security holders may have a difficult time getting a quote for the sale or purchase of our securities, the sale or purchase of our securities
would likely be made more difficult and the trading volume and liquidity of our securities could decline. Delisting from Nasdaq could
also result in negative publicity, result in the termination of our pending Merger and/or make it more difficult for us to find an alternative
business combination, or to complete such Merger or alternative business combination. If our securities are delisted by Nasdaq, our securities
may be eligible to trade on an over-the-counter quotation system, such as the OTCQB Market, where an investor may find it more difficult
to sell our securities or obtain accurate quotations as to the market value of our securities. In the event our securities are delisted
from Nasdaq, we may not be able to list our securities on another national securities exchange or obtain quotation on an over-the counter
quotation system. As a result of the above, we may be forced to abandon our business, liquidate and wind up.
In the event the Trading Halt is not lifted prior
to the delisting of our securities from Nasdaq, security holders will have no way to publicly sell our securities, which may mean they
are forced to hold such securities indefinitely, until or unless we determine to liquidate and wind-up.
Separate from the above, and as previously disclosed
in the Company’s Current Report on Form 8-K filings with the SEC on (a) June 30, 2023, on June 28, 2023, we received a notification
letter from Nasdaq stating the Company was not in compliance with Nasdaq Listing Rule 5450(b)(1)(B), as a result of the number of publicly
held shares of the Company as reported on the Company’s Form 10-K for the period ended December 31, 2022 (i.e., 101,039 shares),
having fallen below the minimum of 1,100,000 publicly held shares required for continued listing — The Nasdaq notification letter
had no immediate effect on the listing of the Company’s units, common stock or warrants on The Nasdaq Global Market. The Nasdaq
notification letter provides the Company until August 14, 2023, to submit a plan to Nasdaq to regain compliance with the Nasdaq’s
continued listing requirements. If the plan is accepted, Nasdaq can grant an exception of up to 180 calendar days, or until December
25, 2023, for the Company to regain compliance. If Nasdaq does not accept the Company’s compliance plan, the Company will have
the opportunity to appeal that decision to a Hearing Panel under Nasdaq Listing Rule 5815(a); and (b) June 16, 2023, on June 13, 2023,
the Company received a notification letter from Nasdaq stating the Company was not in compliance with Nasdaq Listing Rule 5452(b)(C),
as a result of the aggregate market value of the Company’s outstanding warrants falling below the required minimum of $1,000,000
in aggregate market value on June 12, 2023 and for failing to meet the continued Nasdaq listing requirements under alternative standards
— The Nasdaq notification letter had no immediate effect on the listing of the Company’s units, common stock or warrants
on The Nasdaq Global Market. The Nasdaq notification letter provided the Company until July 28, 2023, to submit a plan to Nasdaq to regain
compliance with the Nasdaq’s continued listing requirements. If the plan is accepted, Nasdaq can grant an exception of up to 180
calendar days, or until December 10, 2023, for the Company to regain compliance. If Nasdaq does not accept the Company’s compliance
plan, the Company will have the opportunity to appeal that decision to a Hearing Panel under Nasdaq Listing Rule 5815(a).
The above deficiencies are separate from, and
their potential compliance periods are separate from, the delisting notification received on July 14, 2023, as discussed above, which
delisting notification takes priority over the June 28, 2023 and June 13, 2023 notification letters.
We have identified material weaknesses
in our disclosure controls and procedures and internal control over financial reporting. If not remediated, our failure to establish
and maintain effective disclosure controls and procedures and internal control over financial reporting could result in material misstatements
in our financial statements and a failure to meet our reporting and financial obligations, each of which could have a material adverse
effect on our financial condition and the trading price of our securities.
Maintaining effective internal control over financial
reporting and effective disclosure controls and procedures are necessary for us to produce reliable financial statements. As reported
under “Part II” - “Item 9A. Controls and Procedures” of our Annual Report on Form 10-K for the year ended December
31, 2022, our Management concluded that our disclosure controls and procedures were not effective as of December 31, 2022, due to the
material weaknesses in our internal control over financial reporting of the Company’s Cash accounts and Due from related party
accounts from a failure to segregate bank accounts. In light of the material weaknesses, we performed additional analysis as deemed necessary
to ensure that our unaudited interim financial statements were prepared in accordance with U.S. generally accepted accounting principles
and have restated all financial statements in Note 2 of the financial statements to the Company’s Annual report on Form 10-K which
were affected by such material weaknesses.
Additionally, as of September 30, 2023, as disclosed
above, as required by Rules 13a-15(e) and 15d-15(e) under the Exchange Act, Management carried out an evaluation of the effectiveness
of the design and operation of our disclosure controls and procedures as of September 30, 2023. Based upon their evaluation, Management
concluded that our disclosure controls and procedures were not effective as of September 30, 2023, due to the material weaknesses in
our internal control over financial reporting of the Company’s Cash accounts and Due from related party accounts from a failure
to segregate bank accounts.
A material weakness is a deficiency, or a combination
of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement
of the Company’s annual or interim financial statements will not be prevented or detected on a timely basis. A control deficiency
exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned
functions, to prevent or detect misstatements on a timely basis.
Maintaining effective disclosure controls and
procedures and effective internal control over financial reporting are necessary for us to produce reliable financial statements and
the Company is committed to remediating its material weaknesses in such controls as promptly as possible. However, there can be no assurance
as to when these material weaknesses will be remediated or that additional material weaknesses will not arise in the future. Any failure
to remediate the material weaknesses, or the development of new material weaknesses in our internal control over financial reporting,
could result in material misstatements in our financial statements and cause us to fail to meet our reporting and financial obligations,
which in turn could have a material adverse effect on our financial condition and the trading price of our securities, and/or result
in litigation against us or our management. In addition, even if we are successful in strengthening our controls and procedures, those
controls and procedures may not be adequate to prevent or identify irregularities or facilitate the fair presentation of our financial
statements or our periodic reports filed with the SEC.
Economic uncertainty may affect our access
to capital and/or increase the costs of such capital.
Global economic conditions continue to be volatile
and uncertain due to, among other things, consumer confidence in future economic conditions, fears of recession and trade wars, global
conflicts, including the ongoing conflict between Russia and Ukraine, the price of energy, increasing interest rates, the availability
and cost of consumer credit, the availability and timing of government stimulus programs, levels of unemployment, increased inflation,
and tax rates. These conditions remain unpredictable and create uncertainties about our ability to raise capital in the future. In the
event required capital becomes unavailable in the future, or more costly, it could have a material adverse effect on our business, results
of operations, and financial condition.
Item 2. Unregistered Sales of Equity Securities
and Use of Proceeds
Unregistered Sales of Equity Securities
The Company did not issue or sell any unregistered
equity securities during the quarter ended September 30, 2023, and through the date of the filing of this Report.
Purchases of Equity Securities by the Issuer and Affiliated Purchasers
Neither the Company, nor any affiliated purchasers,
purchased any equity securities during the quarter ended September 30, 2023, and through the date of the filing of this Report.
Use of Proceeds
On December 13, 2021, we consummated our Initial
Public Offering of 22,000,000 Units. On December 21, 2021, we issued an additional 3,300,000 units in connection with the over-allotment
option. All Units were sold at a price of $10.00 per unit, generating gross proceeds to us of approximately $256.8 million.
On our Initial Public Offering closing date,
simultaneously with the consummation of our Initial Public Offering, we completed the private placement of 8,050,000 Private Placement
Warrants at a purchase price of $1.00 per warrant to our Sponsor, generating gross proceeds to us of approximately $8.1 million. On December
21, 2021, we completed the private placement of an additional 825,000 Private Placement Warrants to our Sponsor in connection with the
exercise of the over-allotment option, generating gross proceeds to us of approximately $0.8 million. In total, the private placements
of our Private Placement Warrants in connection with our Initial Public Offering and the over-allotment option generated gross proceeds
of approximately $8.8 million to us.
From March 17, 2021 (inception) through the closing
date of our Initial Public Offering, we incurred approximately $19.0 million for costs and expenses related to our Initial Public Offering.
In connection with our Initial Public Offering, we paid a total of approximately $2.5 million in underwriting discounts and commissions.
In addition, the underwriters agreed to defer approximately $13.9 million in underwriting discounts and commissions, which amount was
to be payable upon consummation of the initial Business Combination. Subsequent to the Initial Public Offering closing date, a total
of $428,000 was repaid to our Sponsor on the Note, out of the proceeds from our Initial Public Offering.
After deducting the underwriting discounts and
commissions (excluding the deferred portion of approximately $13.9 million, which amount will be payable upon consummation of the initial
Business Combination) and offering expenses, the total net proceeds from our Initial Public Offering and the sale of the Private Placement
Warrants were approximately $258.6 million, of which approximately $256.8 million (or $10.15 per unit sold in our Initial Public Offering)
was placed in the Trust Account.
On January 26, 2023, Nomura Securities International,
Inc. (“Nomura”) the underwriter for the initial public offering of the Company, pursuant to a letter dated as of the same
date, waived its entitlement to the payment of the deferred underwriting discount then payable to Nomura in connection with the initial
public offering and pursuant to the prior underwriting agreement between Nomura and the Company dated December 8, 2021. Other than such
waiver, the letter did not waive any rights or obligations of the Company or Nomura which survive the termination of the underwriting
agreement.
The securities sold in our Initial Public Offering
were registered under the Securities Act pursuant to a registration statement on Form S-1 (File Nos. 333-261248 and 333-261559) (the
“Registration Statement”). The SEC declared the Registration Statement effective on December 8, 2021.
No payments for our expenses were made in the
offering described above directly or indirectly to (i) any of our directors, officers or their associates, (ii) any person(s) owning
10% or more of any class of our equity securities or (iii) any of our affiliates, except in connection with the repayment of outstanding
loans. There has been no material change in the planned use of proceeds from our offering as described in our final prospectus filed
with the SEC pursuant to Rule 424(b) related to the Initial Public Offering, filed with the SEC on December 13, 2021.
Item 3. Defaults upon Senior Securities
None.
Item 4. Mine Safety Disclosures
Not applicable.
Item 5. Other Information
To the extent required by Form 8-K and in an
abundance of caution, the following information is being disclosed below instead of pursuant to a Current Report on Form 8-K filed with
the Commission during the period pursuant to Item 1.01 of Form 8-K:
Item 1.01 Entry into a Material Definitive
Agreement.
On January 26, 2023, Nomura Securities International,
Inc. (“Nomura”) the underwriter for the initial public offering of the Company, pursuant to a letter dated as of the same
date, waived its entitlement to the payment of the deferred underwriting discount then payable to Nomura in connection with the initial
public offering and pursuant to the prior underwriting agreement between Nomura and the Company dated December 8, 2021. Other than such
waiver, the letter did not waive any rights or obligations of the Company or Nomura which survive the termination of the underwriting
agreement.
terminated its association with the Company and
waived any fees and compensation in connection with such association, including its entitlement to the payment of any deferred compensation
in connection with its role as underwriter in the Company’s Initial Public Offering.
Item 6. Exhibits
The following exhibits are filed or furnished as a part of, or incorporated
by reference into, this Report.
No. |
|
Description
of Exhibit |
2.1 |
|
Termination
of Agreement and Plan of Merger Agreement dated August 16, 2023, by and between Genesis Growth Tech Acquisition Corp., GGAC Merger
Sub, Inc., Eyal Perez, NextTrip Holdings, Inc. and William Kerby (filed as Exhibit 10.1 to the Company’s Current Report on
Form 8-K, filed with the SEC on August 16, 2023)( File No.: 001-41138) |
|
|
|
3.1 |
|
Second
Amended and Restated Memorandum and Articles of Association of Genesis Growth Tech Acquisition Corp. (filed as Exhibit 3.1 to the
Company’s Current Report on Form 8-K, filed with the SEC on February 22, 2023)( File No.: 001-41138) |
|
|
|
10.1* |
|
January 26, 2023 Waiver Letter from Nomura Securities International, Inc. to Genesis Growth Tech Acquisition Corp. |
|
|
|
10.2 |
|
Termination
of Business Combination Agreement dated March 6, 2023, by and between Biolog-ID S.A and Genesis Growth Tech Acquisition Corp. (filed
as Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed with the SEC on March 6, 2023)( File No.: 001-41138) |
|
|
|
16.1 |
|
Letter
of Citrin Cooperman & Company, LLP dated April 17, 2023 (filed as Exhibit 16.1 to the Company’s Current Report on Form
8-K, filed with the SEC on April 17, 2023)( File No.: 001-41138) |
|
|
|
16.2 |
|
Letter
from Citrin Cooperman & Company, LLP dated May 23, 2023 (filed as Exhibit 16.1 to the Company’s Current Report on Form
8-K/A, filed with the SEC on May 24, 2023)( File No.: 001-41138) |
|
|
|
16.3 |
|
Letter
from Citrin Cooperman & Company, LLP dated May 24, 2023 (filed as Exhibit 99.1 to the Company’s Current Report on Form
8-K/A, filed with the SEC on May 24, 2023)( File No.: 001-41138) |
|
|
|
31.1* |
|
Certification of Principal Executive Officer and Principal Financial and Accounting Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |
|
|
|
32.1** |
|
Certification of Principal Executive Officer and Principal Financial and Accounting Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |
|
|
|
101.INS* |
|
Inline XBRL Instance Document |
|
|
|
101.CAL* |
|
Inline XBRL Taxonomy Extension
Calculation Linkbase Document |
|
|
|
101.SCH* |
|
Inline XBRL Taxonomy Extension
Schema Document |
|
|
|
101.DEF* |
|
Inline XBRL Taxonomy Extension
Definition Linkbase Document |
|
|
|
101.LAB* |
|
Inline XBRL Taxonomy Extension
Labels Linkbase Document |
|
|
|
101.PRE* |
|
Inline XBRL Taxonomy Extension
Presentation Linkbase Document |
|
|
|
104* |
|
Cover Page Interactive
Data File (formatted as Inline XBRL and contained in Exhibit 101) |
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Dated: November 9, 2023 |
GENESIS
GROWTH TECH ACQUISITION CORP. |
|
|
|
|
By: |
/s/
Eyal Perez |
|
|
Name: |
Eyal Perez |
|
|
Title: |
Chief Executive Officer,
Chief Financial Officer and Director
(Principal Executive Officer and
Principal Financial and Accounting Officer) |
33
25300000
25300000
4990857
94250
0.00
0.01
0.05
0.08
6325000
6325000
6325000
6325000
0.00
0.01
0.05
0.08
25300000
6325000
6325000
94250
0.00
0.00
0.05
0.05
25300000
4990857
6325000
6325000
0.01
0.01
0.08
0.08
false
--12-31
Q3
0001865697
0001865697
2023-01-01
2023-09-30
0001865697
ggaa:UnitsEachConsistingOfOneClassAOrdinaryShareAndOnehalfOfOneRedeemableWarrantMember
2023-01-01
2023-09-30
0001865697
ggaa:ClassAOrdinarySharesParValue00001PerShareIncludedAsPartOfTheUnitsMember
2023-01-01
2023-09-30
0001865697
ggaa:WarrantsEachWholeWarrantExercisableForOneClassAOrdinaryShareAtAnExercisePriceOf1150PerShareMember
2023-01-01
2023-09-30
0001865697
us-gaap:CommonClassAMember
2023-11-09
0001865697
us-gaap:CommonClassBMember
2023-11-09
0001865697
2023-09-30
0001865697
2022-12-31
0001865697
us-gaap:RelatedPartyMember
2023-09-30
0001865697
us-gaap:RelatedPartyMember
2022-12-31
0001865697
us-gaap:CommonClassAMember
2023-09-30
0001865697
us-gaap:CommonClassAMember
2022-12-31
0001865697
us-gaap:CommonClassBMember
2023-09-30
0001865697
us-gaap:CommonClassBMember
2022-12-31
0001865697
2023-07-01
2023-09-30
0001865697
2022-07-01
2022-09-30
0001865697
2022-01-01
2022-09-30
0001865697
us-gaap:RelatedPartyMember
2023-07-01
2023-09-30
0001865697
us-gaap:RelatedPartyMember
2022-07-01
2022-09-30
0001865697
us-gaap:RelatedPartyMember
2023-01-01
2023-09-30
0001865697
us-gaap:RelatedPartyMember
2022-01-01
2022-09-30
0001865697
us-gaap:CommonClassAMember
2023-07-01
2023-09-30
0001865697
us-gaap:CommonClassAMember
2022-07-01
2022-09-30
0001865697
us-gaap:CommonClassAMember
2023-01-01
2023-09-30
0001865697
us-gaap:CommonClassAMember
2022-01-01
2022-09-30
0001865697
us-gaap:CommonClassBMember
2023-07-01
2023-09-30
0001865697
us-gaap:CommonClassBMember
2022-07-01
2022-09-30
0001865697
us-gaap:CommonClassBMember
2023-01-01
2023-09-30
0001865697
us-gaap:CommonClassBMember
2022-01-01
2022-09-30
0001865697
us-gaap:CommonClassAMember
us-gaap:CommonStockMember
2022-12-31
0001865697
us-gaap:CommonClassBMember
us-gaap:CommonStockMember
2022-12-31
0001865697
us-gaap:AdditionalPaidInCapitalMember
2022-12-31
0001865697
us-gaap:RetainedEarningsMember
2022-12-31
0001865697
us-gaap:CommonClassAMember
us-gaap:CommonStockMember
2023-01-01
2023-03-31
0001865697
us-gaap:CommonClassBMember
us-gaap:CommonStockMember
2023-01-01
2023-03-31
0001865697
us-gaap:AdditionalPaidInCapitalMember
2023-01-01
2023-03-31
0001865697
us-gaap:RetainedEarningsMember
2023-01-01
2023-03-31
0001865697
2023-01-01
2023-03-31
0001865697
us-gaap:CommonClassAMember
us-gaap:CommonStockMember
2023-03-31
0001865697
us-gaap:CommonClassBMember
us-gaap:CommonStockMember
2023-03-31
0001865697
us-gaap:AdditionalPaidInCapitalMember
2023-03-31
0001865697
us-gaap:RetainedEarningsMember
2023-03-31
0001865697
2023-03-31
0001865697
us-gaap:CommonClassAMember
us-gaap:CommonStockMember
2023-04-01
2023-06-30
0001865697
us-gaap:CommonClassBMember
us-gaap:CommonStockMember
2023-04-01
2023-06-30
0001865697
us-gaap:AdditionalPaidInCapitalMember
2023-04-01
2023-06-30
0001865697
us-gaap:RetainedEarningsMember
2023-04-01
2023-06-30
0001865697
2023-04-01
2023-06-30
0001865697
us-gaap:CommonClassAMember
us-gaap:CommonStockMember
2023-06-30
0001865697
us-gaap:CommonClassBMember
us-gaap:CommonStockMember
2023-06-30
0001865697
us-gaap:AdditionalPaidInCapitalMember
2023-06-30
0001865697
us-gaap:RetainedEarningsMember
2023-06-30
0001865697
2023-06-30
0001865697
us-gaap:CommonClassAMember
us-gaap:CommonStockMember
2023-07-01
2023-09-30
0001865697
us-gaap:CommonClassBMember
us-gaap:CommonStockMember
2023-07-01
2023-09-30
0001865697
us-gaap:AdditionalPaidInCapitalMember
2023-07-01
2023-09-30
0001865697
us-gaap:RetainedEarningsMember
2023-07-01
2023-09-30
0001865697
us-gaap:CommonClassAMember
us-gaap:CommonStockMember
2023-09-30
0001865697
us-gaap:CommonClassBMember
us-gaap:CommonStockMember
2023-09-30
0001865697
us-gaap:AdditionalPaidInCapitalMember
2023-09-30
0001865697
us-gaap:RetainedEarningsMember
2023-09-30
0001865697
us-gaap:CommonClassAMember
us-gaap:CommonStockMember
2021-12-31
0001865697
us-gaap:CommonClassBMember
us-gaap:CommonStockMember
2021-12-31
0001865697
us-gaap:AdditionalPaidInCapitalMember
2021-12-31
0001865697
us-gaap:RetainedEarningsMember
2021-12-31
0001865697
2021-12-31
0001865697
us-gaap:CommonClassAMember
us-gaap:CommonStockMember
2022-01-01
2022-03-31
0001865697
us-gaap:CommonClassBMember
us-gaap:CommonStockMember
2022-01-01
2022-03-31
0001865697
us-gaap:AdditionalPaidInCapitalMember
2022-01-01
2022-03-31
0001865697
us-gaap:RetainedEarningsMember
2022-01-01
2022-03-31
0001865697
2022-01-01
2022-03-31
0001865697
us-gaap:CommonClassAMember
us-gaap:CommonStockMember
2022-03-31
0001865697
us-gaap:CommonClassBMember
us-gaap:CommonStockMember
2022-03-31
0001865697
us-gaap:AdditionalPaidInCapitalMember
2022-03-31
0001865697
us-gaap:RetainedEarningsMember
2022-03-31
0001865697
2022-03-31
0001865697
us-gaap:CommonClassAMember
us-gaap:CommonStockMember
2022-04-01
2022-06-30
0001865697
us-gaap:CommonClassBMember
us-gaap:CommonStockMember
2022-04-01
2022-06-30
0001865697
us-gaap:AdditionalPaidInCapitalMember
2022-04-01
2022-06-30
0001865697
us-gaap:RetainedEarningsMember
2022-04-01
2022-06-30
0001865697
2022-04-01
2022-06-30
0001865697
us-gaap:CommonClassAMember
us-gaap:CommonStockMember
2022-06-30
0001865697
us-gaap:CommonClassBMember
us-gaap:CommonStockMember
2022-06-30
0001865697
us-gaap:AdditionalPaidInCapitalMember
2022-06-30
0001865697
us-gaap:RetainedEarningsMember
2022-06-30
0001865697
2022-06-30
0001865697
us-gaap:CommonClassAMember
us-gaap:CommonStockMember
2022-07-01
2022-09-30
0001865697
us-gaap:CommonClassBMember
us-gaap:CommonStockMember
2022-07-01
2022-09-30
0001865697
us-gaap:AdditionalPaidInCapitalMember
2022-07-01
2022-09-30
0001865697
us-gaap:RetainedEarningsMember
2022-07-01
2022-09-30
0001865697
us-gaap:CommonClassAMember
us-gaap:CommonStockMember
2022-09-30
0001865697
us-gaap:CommonClassBMember
us-gaap:CommonStockMember
2022-09-30
0001865697
us-gaap:AdditionalPaidInCapitalMember
2022-09-30
0001865697
us-gaap:RetainedEarningsMember
2022-09-30
0001865697
2022-09-30
0001865697
us-gaap:IPOMember
2021-12-13
2021-12-13
0001865697
us-gaap:IPOMember
2021-12-13
0001865697
ggaa:UnderwritersMember
2021-12-13
2021-12-13
0001865697
us-gaap:OverAllotmentOptionMember
2021-12-21
2021-12-21
0001865697
us-gaap:IPOMember
2021-12-21
0001865697
2021-12-21
2021-12-21
0001865697
us-gaap:PrivatePlacementMember
2023-09-30
0001865697
ggaa:SponsorMember
us-gaap:PrivatePlacementMember
2023-01-01
2023-09-30
0001865697
ggaa:PrivatePlacementWarrantMember
2021-12-21
0001865697
ggaa:PrivatePlacementWarrantMember
2021-12-21
2021-12-21
0001865697
us-gaap:OverAllotmentOptionMember
2023-01-01
2023-09-30
0001865697
us-gaap:OverAllotmentOptionMember
2023-09-30
0001865697
ggaa:BusinessCombinationMember
2023-09-30
0001865697
us-gaap:IPOMember
2023-01-01
2023-09-30
0001865697
ggaa:SponsorMember
2022-12-09
0001865697
ggaa:SponsorMember
2023-09-30
0001865697
2023-08-31
0001865697
2023-08-31
2023-08-31
0001865697
us-gaap:CommonClassAMember
2023-08-31
2023-08-31
0001865697
us-gaap:CommonClassAMember
2023-08-31
0001865697
us-gaap:IPOMember
2023-08-31
0001865697
2022-12-30
0001865697
ggaa:SponsorMember
2023-09-30
0001865697
ggaa:SponsorMember
2022-12-31
0001865697
us-gaap:IPOMember
2023-09-30
0001865697
ggaa:PrivatePlacementWarrantsMember
2023-09-30
0001865697
us-gaap:CommonClassAMember
ggaa:TemporaryEquityMember
2023-09-30
0001865697
us-gaap:CommonClassAMember
ggaa:TemporaryEquityMember
2022-12-31
0001865697
us-gaap:CommonClassAMember
ggaa:PrivatePlacementWarrantsMember
2023-01-01
2023-09-30
0001865697
us-gaap:OverAllotmentOptionMember
2021-12-21
0001865697
2021-12-21
0001865697
ggaa:SponsorMember
2021-05-26
2021-05-26
0001865697
ggaa:SponsorMember
2021-05-26
0001865697
ggaa:SponsorMember
us-gaap:CommonClassBMember
2021-05-26
2021-05-26
0001865697
ggaa:SponsorMember
us-gaap:CommonClassBMember
2021-05-26
0001865697
ggaa:SponsorMember
us-gaap:CommonClassBMember
2021-09-01
2021-09-20
0001865697
ggaa:SponsorMember
us-gaap:CommonClassBMember
2021-12-08
0001865697
ggaa:SponsorMember
2021-12-31
2021-12-31
0001865697
ggaa:SponsorMember
ggaa:FounderSharesMember
2023-01-01
2023-09-30
0001865697
ggaa:FounderSharesMember
2023-01-01
2023-09-30
0001865697
us-gaap:PrivatePlacementMember
2021-12-21
0001865697
us-gaap:PrivatePlacementMember
2021-12-21
2021-12-21
0001865697
ggaa:PrivatePlacementWarrantsMember
2021-12-21
2021-12-21
0001865697
ggaa:PrivatePlacementWarrantsMember
2021-12-21
0001865697
2022-12-09
0001865697
us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember
2023-01-01
2023-09-30
0001865697
us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember
2021-12-08
2021-12-08
0001865697
2022-01-01
2022-12-31
0001865697
2023-06-20
0001865697
ggaa:PublicWarrantsMember
2023-09-30
0001865697
ggaa:PublicWarrantsMember
2022-12-31
0001865697
us-gaap:PrivatePlacementMember
2022-12-31
0001865697
us-gaap:WarrantMember
2023-01-01
2023-09-30
0001865697
us-gaap:WarrantMember
us-gaap:CommonClassAMember
2023-01-01
2023-09-30
0001865697
us-gaap:FairValueInputsLevel1Member
2023-09-30
0001865697
us-gaap:FairValueInputsLevel2Member
2023-09-30
0001865697
us-gaap:FairValueInputsLevel3Member
2023-09-30
0001865697
us-gaap:FairValueInputsLevel1Member
2022-12-31
0001865697
us-gaap:FairValueInputsLevel2Member
2022-12-31
0001865697
us-gaap:FairValueInputsLevel3Member
2022-12-31
xbrli:shares
iso4217:USD
iso4217:USD
xbrli:shares
xbrli:pure
Genesis Growth Tech Acquisition Corp.
Attention: Albert Vanderlaan, Esq.
Reference is made to the
underwriting agreement, dated December 8, 2021 (the “Agreement”), among Genesis Growth Tech Acquisition Corp., a Cayman Islands
exempted company (the “Company”) and Nomura Securities International, Inc. (“Nomura”) on behalf of itself and
as representative of the several underwriters named therein, pursuant to which Nomura was engaged to render certain underwriting services
to the Company in connection with the Company’s initial public offering. Unless otherwise defined, capitalized terms used herein
have the meanings assigned to such terms in the Agreement.
Whereas (i) pursuant to Section 1(b) of the Agreement
Nomura is entitled to receive Underwritten Deferred Discount upon consummation of the Business Combination and (ii) pursuant to Section
l(d) of the Agreement Nomura is entitled to receive Option Deferred Discount (and together with the Underwritten Deferred Discount, the
“Deferred Discount”), Nomura hereby waives on behalf of itself, effective as of the date hereof, its entitlement to the payment
of any and all amounts of Deferred Discount now owing to Nomura or subsequently payable to Nomura in accordance with the Agreement; provided,
however, Nomura’s Deferred Discount waiver shall not affect any rights and obligations of the Company or of Nomura which by their
terms survived expiration of the Agreement and provided further that Nomura’s Deferred Discount waiver shall not affect any rights
of any other underwriter of the Company’s initial public offering.
Nomura’s Underwritten Deferred Discount
waiver is not the result of any dispute or disagreement with the Company or any Business Combination target or any of their respective
affiliates.
This letter, and any claim,
controversy or dispute arising under or related to this letter, shall be governed by and construed in accordance with the laws of the
State of New York without reference to principles of conflicts of law.
Nomura Securities International, Inc.
I, Eyal Perez, certify,
as of the date hereof, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that
the Quarterly Report of Genesis Growth Tech Acquisition Corp. on Form 10-Q for the period ended September 30, 2023 fully complies with
the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and that the information contained in such
Form 10-Q fairly presents in all material respects the financial condition and results of operations of Genesis Growth Tech Acquisition
Corp. at the dates and for the periods indicated.